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Recent evidence suggests that individual amino acids may promote hypophagia, 
however, our understanding of processes underlying their anorexigenic action is 
extremely limited. The few human and laboratory animal studies performed to date 
suggest that a free essential amino acid, l-tryptophan (TRP) reduces food intake. It 
is unclear, however, whether TRP acutely affects consumption driven by energy 
needs or by palatability, and whether central mechanisms underlie TRP-induced 
hypophagia. This thesis provides a detailed characterisation of ingestive 
behavioural effects induced by TRP administered intragastrically or (in order to 
bypass the gut) via an intraperitoneal (IP) injection in laboratory rodents prior to a 
meal as well as relevant neural processes triggered by TRP. 
The first set of experiments explored whether an intragastric preload of TRP affects 
energy- and palatability-induced feeding in mice. A conditioned taste aversion 
(CTA) test was used to assess whether hypophagia is unrelated to sickness. Finally, 
c-Fos immunohistochemistry was employed to detect changes in activation of 
feeding-related brain sites induced by an anorexigenic dose of intragastric TRP. 
TRP generated a short-lasting reduction in the intake of energy-dense standard 
chow in deprived animals and energy-dense palatable chow in sated mice. 
Anorexigenic doses of TRP did not cause a CTA. TRP failed to affect intake of 
palatable yet calorie-dilute or noncaloric solutions (10% sucrose, 4.1% Intralipid or 
0.1% saccharin) even for higher TRP doses that decreased water intake in thirsty 
mice. c-Fos analysis revealed an increase in activation of key feeding-related brain 




found to diminish energy-driven food consumption as well as (at high doses) thirst-
induced water intake and affect activation of relevant central circuits. 
In the second set of experiments, I investigated whether anorexigenic and brain 
activation effects persist when TRP bypasses the gut, i.e., TRP is injected directly 
in the IP cavity in rats. The effect of IP TRP was examined in both energy- and 
palatability-induced feeding. 30 and 100 mg/kg IP TRP suppressed chow intake in 
energy deprived rats. Only a higher 100 mg/kg IP TRP dose reduced consumption 
of palatable chow and palatable sucrose, saccharin and Intralipid solutions in sated 
animals. Thirst-driven water intake was reduced after 30 and 100 mg/kg IP TRP. 
Neither 30 nor 100 mg/kg IP TRP caused a CTA. c-Fos analysis showed the most 
pronounced effect of IP TRP on hypothalamic paraventricular (PVN) and 
supraoptic (SON) nuclei and the nucleus of the solitary tract in the brainstem. It can 
be concluded that IP TRP suppresses energy deprivation-induced intake of chow 
and thirst-induced water intake within the same dose range, whereas higher doses 
are necessary to reduce consumption of palatable solutions in sated animals. IP TRP 
hypophagia is accompanied by activation of central circuitry that encompasses 
brainstem and hypothalamic sites, though changes are not as prominent as with 
intragastric TRP. 
Intragastric and IP TRP administered at hypophagic doses increases c-Fos 
immunoreactivity in the hypothalamic PVN and SON. As these sites host neurons 
that synthesise a key satiety mediator, oxytocin (OT), the third and final set of 
studies explored a hypothesis that TRP’s anorexigenic action relies on enhanced 




determined that the lowest effective dose of intragastric and IP TRP increased the 
activation of both PVN and SON OT neurons, although the effect was more 
pronounced after intragastric administration. Intragastric TRP upregulated OT 
mRNA in the hypothalamus. A blood-brain barrier-penetrant OT receptor 
antagonist, L-368,899, reversed hypophagia induced by TRP administered via both 
routes. Unlike the lowest effective dose of intragastric TRP which decreases only 
feeding, IP TRP at the lowest effective dose diminishes both food and water intake. 
Hence it was confirmed that L-368,899 pre-treatment does not affect TRP-driven 
reduction in drinking. The findings suggest therefore a functional relationship 
between TRP and OT in the regulation of energy-driven food intake. 
Overall, the findings presented herein shed more light on the nature of anorexigenic 
properties of TRP. It appears that TRP acutely suppresses ingestive behaviour 
driven by energy, but it is a very weak inhibitor of palatability-motivated 
consumption. While both intragastric and IP TRP also decreased water intake, the 
fact that a low dose of the intragastric amino acid was sufficient to decrease feeding 
but not drinking, strongly suggests that a direct interaction of TRP with the gastric 
mucosa is a crucial contributor to reduced energy intake. TRP engages broad brain 
circuits relevant to feeding, especially the hypothalamus and brainstem. OT appears 
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1 Chapter One – Introduction and Aims 
Despite developments over the past few decades in the prevention, management 
and treatment of obesity, New Zealand has the third highest prevalence of this 
health problem amongst the Organisation for Economic Cooperation and 
Development (OECD) countries. The New Zealand clinical obesity rate is currently 
1 in 3 adults – with a further third being deemed overweight [1]. The condition is 
often associated with multiple co-morbidities, including cardiovascular (CVS) 
disease, diabetes and certain cancers [2-5]. Obesity develops when an individual’s 
energy intake habitually exceeds energy expenditure, resulting in weight gain [6-9]. 
Excessive weight gain can often be attributed to the dysregulation of mechanisms 
that control hunger and promote satiety [10].  
However, humans and laboratory animals eat not only to satisfy calorie needs, but 
also for reward [11]. To a large extent, feeding reward stems from palatability of 
tastants, and that is derived from – among others – specific macronutrient 
composition and pleasant taste. While it is unquestionable that high-fat/high-sugar 
diets have propelled the obesity ‘epidemic’, this phenomenon has also generated 
hope that certain dietary manipulations might have an opposite effect, paving a way 
toward developing ‘functional foods’ whose composition will curb excessive 
consumption. One of the early strategies has been to increase protein content in 
diets. As high protein content impairs palatability and acceptability of food item 
[12-18], this approach has had only a limited success due to patients’ poor 
adherence to therapies. Later it was hypothesised that certain free amino acids might 




adding whole protein. Indeed, though evidence is still relatively scarce, the early 
findings imply that certain single amino acids (including the one selected for this 
project L-tryptophan (TRP) may act as feeding inhibitors [19, 23, 25-29]. Therefore, 
the current thesis focused on defining a potential hypophagic action of TRP and 
examining whether brain circuits that promote satiety are activated by this essential 
amino acid.    
1.1 Protein intake and appetite 
Initial studies in the 1970’s by Booth and colleagues compared satiety responses in 
human subjects receiving either protein-rich (40%) or protein-poor (9.1%) 
isocaloric crispbread lunches. When an identical supplementary meal was provided 
three hours later, the total caloric intake in that meal was less for those provided 
with the higher protein option [30]. 
Since then, several decades of research, in both humans and laboratory animals, 
have found suppression of food intake and body weight loss to be associated with 
high-protein diets [12-18]. For humans, the recommended level of dietary protein 
intake is 10-15% of total energy, when an individual is in energy balance and at a 
stable weight [31]. A human study compared caloric intake and bodyweight change 
achieved through a 15% protein diet and a 30% protein diet. Participants received 
a fixed volume baseline diet (15% protein, 35% fat and 50% carbohydrate), then a 
high protein, isocaloric, fixed volume diet (30% protein, 20% fat and 50% 
carbohydrate) each for two weeks. For subsequent 12 weeks, participants were 
given ad libitum access to the high protein diet [14]. A sustained reduction in ad 




three macronutrients (proteins, carbohydrates and fats), protein has been identified 
as the strongest inhibitor of food intake [12, 15, 18, 32-36]. In a cohort of young 
adults, provision of either an isocaloric (240-kcal) high-protein (77% of energy 
from protein), high-carbohydrate (84%) or high-fat (58%) snack promoted satiety 
as observed in the increased latency to request for dinner by 60, 34 and 25 minutes 
respectively [33]. In rats, delivery of isoenergetic loads of protein (35% and 50% 
gluten load) via intraoral cannula induced a greater reduction in appetite, compared 
to animals given an isocaloric starch (carbohydrate) 0% gluten load [15].  
However, these aforementioned high-protein diets tend to have diminished 
palatability,  greatly reducing consumption of food for reward [37]. McArthur and 
colleagues trained rats (over two-weeks) to eat daily for a 3-hour period, first 
utilising a basal 20% casein-based diet, followed by a low protein diet (6% casein) 
for 5 weeks. A higher protein (75% casein) diet was then given for a day which 
prompted a significant decrease in food intake. This suppression was evident after 
one minute – too short a time period for the metabolic effects of the diet to be seen 
– thereby indicating the early depression of food intake being due to poor initial 
palatability [37]. Importantly, Bensaid and colleagues demonstrated that rats 
rapidly reduced intake of a high-protein diet (50% milk protein). Over time this 
consumption increased, though not to the consistently high level previously 
achieved with a low-protein diet (14% milk protein). This was not due to an 
acquired conditioned taste aversion (CTA) but the initial lower palatability of the 
diet [38]. As a CTA transpires when an animal associates the given novel flavour 
with a gastrointestinal (GI) discomfort, this effect could not have been attributed to 




The past decades of research have sparked interest in identifying the physiological 
mechanisms that are involved in protein-induced hypophagia. There is possible 
epidemiological value of these protein-based strategies for overcoming obesity. The 
intake of protein triggers postoral and postabsorptive mechanisms at both the 
central and peripheral level [12-14]. Within the GI tract, endocrine processes begin 
with the release of cholecystokinin (CCK), glucagon-like peptide (GLP-1) and 
peptide YY (PYY) (Figure 1.1) [15, 40-45]. Along with the suppression of the 
hormone ghrelin, altogether it results in an overall reduction in appetite and food 
consumption (promote early satiation) [46, 47]. Satiation signals are within-meal 
signals that lead to meal termination [48, 49]. Some of these satiation signalling 
molecules can act directly in the brain by crossing the blood brain barrier (BBB) 
[47], whereas others such as CCK, affect the brain via the vagus nerve terminating 
in the brainstem (the nucleus of the solitary tract (NTS) and area postrema (AP)) 
[48, 50, 51]. These hormones then trigger activation of a broader network of sites 
involved in appetite regulation (discussed further in Section 1.5). The cessation of 
eating in its most fundamental and basic integrative form is an interaction between 
both the hypothalamic and hindbrain nuclei to control satiation and satiety [52]. 
Once in the GI tract, proteins are digested to amino acids, which act directly at the 
gut mucosa, eventually affecting motility and endocrine signals, via interaction with 
ubiquitous G-protein coupled receptors and transporters [22]. Ultimately, the amino 
acids can directly enter the bloodstream to act peripherally and – in some cases – 






Figure 1.1 Examples of endocrine pathways involved in 




The appetite suppressant action of high-protein diets has been well documented in 
both humans and animal models. Proteins once consumed are digested to release 






1.1.1 Amino acids and food intake 
Amino acids are now known to be involved in the central regulation of food intake, 
energy homeostasis and body weight [19-24]. Research has identified a number of 
individual amino acids (e.g. L-leucine, L-arginine, L-lysine, L-cysteine, TRP and 
L-glutamic acid), that can act as potent anorexigens [19, 23, 25-29]. One of the most 
extensively studied is leucine – which has consistently caused a reduction of food 
intake when administered centrally [19, 26, 53, 54]. Cota and colleagues (2006) 
demonstrated that central infusions of leucine into the third ventricle suppressed 
food intake via the regulation of mammalian target of rapamycin signalling (mTOR) 
in mice [19]. Moreover, leucine-induced anorexia could be reversed by the 
intracerebroventricular (ICV) administration of rapamycin [19, 26, 53, 54], a 
specific inhibitor of mTOR [55, 56]. Interestingly, leucine has a dual effect on food 
intake as – unlike centrally acting amino acid - peripheral administration increases 
food consumption [57-60], though the underlying mechanism is unclear. 
Of late, an array of studies further identified individual amino acids with 
anorexigenic potential [19, 23, 25-29]. Following either intragastric or 
intraperitoneal (IP) administration of L-cysteine, in both rat and obese mouse 
models a dose-dependent reduction in food intake was reported [27]. L-cysteine 
showed increased neuronal activation in the AP, a brainstem region known to be 
associated with energy homeostasis [23, 27]. 
Alamshah et al. (2016) discovered that L-arginine when given to rodents via oral 
gavage, IP and ICV infusions, all reduced 1-hour food intake. In diet-induced obese 




cumulative 24-hour intake. The reported reduction in food intake was determined 
to not be mediated via either GLP-1/PYY or via the vagus, thereby indicating that 
L-arginine may be directly acting on the brain to influence feeding [25]. L-
arginine’s anorectic potential had previously been suggested by Jordi et al., (2013) 
[23]. That study analysed all 20 amino acids by giving rats an intragastric isomolar 
dose of 6.7mmol/kg of selected amino acids. L-arginine and L-lysine were 
identified as the most potent anorectic amino acids. The suggested common 
mechanism of action for these amino acids is the activation of brainstem circuitry 
(through the AP and/or vagus-facilitated processing) [23]. 
The essential amino acid TRP is thought to impact appetite, but the exact nature of 
such changes in feeding remains to be elucidated. Some initial studies have 
demonstrated moderate hypophagia following both TRP supplementation and 
administration [23, 28, 29]. The daily dietary supplementation of TRP at 3.0 g/kg 
body weight decreased food intake in ad libitum-fed rats by approximately 25%. 
The reduction was due to changes in the observed meal pattern, most notably an 
increase in intermeal intervals and decreased meal number [29]. The intragastric 
administration of 200-600 mg/kg TRP has been found to cause a similar reduction 
in intake in rats maintained on the 12-h/day availability schedule of both standard 
and high-carbohydrate (protein-free) food [28]. However, Jordi and colleagues 
reported that although rats treated with intragastric TRP (6.7 mmol/kg) consumed 
less upon the refeeding of standard laboratory chow after 12 h of fasting, the 
decrease did not reach the level of statistical significance which the authors 
attributed to multiple comparisons performed in the analysis [23]. The above 




produce an anorexigenic effect and indicate that TRP appears to be a candidate 
molecule to promote hypophagia. 
1.2 Tryptophan  
TRP is a branched-chain large neutral amino acid (LNAA). The molecule contains 
an α-amino group, an α-carboxylic acid group, and a side chain indole ring thereby 
classifying it as a non-polar, aromatic amino acid (Figure 1.2) [61]. TRP is an 
essential amino acid, hence it must be supplied via the consumption of dietary 
proteins as it cannot be synthesised by the organism itself [62].  The typical role for 
TRP is protein synthesis but it also serves as a precursor in multiple biochemical 
and functional pathways in the periphery and in central nervous system (CNS) [63-
65]. This includes the production of kynurenine, serotonin (5-HT), melatonin and 
niacin [63, 66-70].  These substances affect several physiological processes, for 
example, sleep/wake cycle, mood, circadian rhythms, cognition, memory and the 
central regulation of appetite [64, 65, 71-75]. 
 
 





After consumption, proteins are digested and broken into their constituent amino 
acids. The absorption of TRP occurs quickly, and TRP enters the general circulation 
from the GI tract in a dose-dependent manner in minutes [28, 29, 76]. Ng and 
Anderson (1992) showed that both plasma and brain TRP increased for 30 minutes 
after delivery of 100 mg/kg dose via IP injection and, to a lesser degree, after 
intragastric infusion [28]. The uptake of TRP and other neutral amino acids occurs 
via the apical membrane of the intestinal absorptive cells using the epithelial 
transporter B0AT1 [77]. Within the enterocytes’ basolateral membrane is the 
aromatic amino acid transporter (TAT1), responsible for the transportation across 
the membrane and into the adjacent cells [77]. Eventually, TRP will directly enter 
the circulation where it is commonly bound to serum albumin via its indole ring 
(Figure 1.2) [78]. This contrasts with the other amino acids which typically remain 
free [61, 79]. Interestingly, the binding site of albumin has poor affinity for TRP 
and, due to competition from free fatty acids (FFA) and other drugs for the same 
site, some will remain unbound in the general circulation [76, 79, 80]. In fact, the 
binding of TRP to albumin may also have a minor influence on the transportation 
of TRP via large neutral amino acid (LAT1) transporter across the BBB [81].  
From the general circulation, TRP can directly cross the BBB [82, 83]. TRP is 
competitively transported across the BBB by LAT1 that is located on the capillary 
endothelial cells. LAT1 is highly expressed on the luminal side of the BBB 
endothelium [84]. This transporter binds other LNAA with similar affinities as TRP, 
therefore, the uptake of TRP by LAT1 is influenced by the plasma ratio of TRP to 
these other LNAA/BCAA [85-90]. Plasma concentrations of TRP, and BBB 




[91]. Simply increasing the TRP dietary content exhibits increased uptake of TRP 
across the BBB [83, 92]. The chronic ingestion of different protein sources, for 
example, gluten, soy, casein, or α-lactalbumin, induced altered brain TRP levels in 
rats [93]. 
Research has revealed that BBB transporters of amino acids act selectively [94]. 
Administration of radiolabelled amino acids in rats demonstrated preferential 
uptake (5-10 times greater) for essential over non-essential amino acids [95, 96]. 
The LAT1 transporter is the predominant amino acid transporter in the BBB and is 
responsible for the transport of most essential amino acids from the luminal side 
[84, 97, 98]. Abluminally expressed transporters export amino acids across the BBB 
back into general circulation [97, 99]. Therefore, the BBB can control both the 
import and export of amino acids to regulate central levels [94]. 
1.2.1 Metabolic fates and key pathways of tryptophan 
The predominant proportion of ingested dietary TRP is utilised via peripheral 
pathways as compared to central routes [63]. Additional to its role in the periphery, 
TRP is a biochemical precursor in the CNS for, among others, neuroactive 
metabolites that are key in appetite regulation. Dietary TRP contributes to several 
metabolic and functional pathways; protein synthesis, kynurenine and serotonergic 





Figure 1.3 Key metabolic and functional pathways of tryptophan 
 
1.2.1.1 Protein synthesis 
As an essential amino acid, TRP must be provided by dietary protein sources [62-
65]. While no consensus has been reached on the exact proportion of dietary TRP 
utilised for protein synthesis [63, 100], Allegri and associates used in vitro enzyme 
determination in mammals to provide a 30% estimate [101]. At low levels, TRP 
acts as a rate-limiting amino acid in protein synthesis [102]. Interestingly, mice fed 
a sole TRP diet, when compared to those on a balanced amino acid diet, displayed 
enhanced hepatic protein synthesis. This effect was not observed with other amino 
acids, such as isoleucine, threonine or methionine [103].  
 The proportion of dietary TRP required for protein synthesis also varies with the 




growing animals obviously have higher TRP requirements for protein growth and 
accretion compared to adults of the same species [104, 105].  
1.2.2 Kynurenine pathway 
The predominant metabolic fate for TRP is entry into the kynurenine pathway, some 
authors suggesting that it applies up to 90% of dietary TRP [63, 68, 100]. This 
pathway is the primary route by which TRP levels are regulated catabolically [68, 
100]. TRP is an intermediary product in the complex kynurenine pathway, 
producing many metabolites (nicotinamide, carbon dioxide, kynurenic, picolinic, 
quinolinic and xanthurenic acids) which are active within both peripheral and 
central nervous systems [106-110]. These metabolites are involved in numerous 
physiological functions, including GI motility, neuroprotective and neurotoxic 
actions [111]. 
Circulatory TRP is the precursor of N-formylkynurenine and gets converted to 
kynurenine by the enzyme kynurenine formadase, which is a rate limiting process 
[112]. There are two enzymes that catalyse the reaction – tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). These two enzymes 
differ in various characteristics (summarised in Table 1), of note their organ 
distribution [64]. TDO is primarily found in the liver [113, 114] whereas IDO is 
found in both central and peripheral tissues, especially the small intestine [64]. 
Central expression is localised in astrocytes, microglia, brain-infiltrating 
macrophages and dendritic cells [115, 116], mediating the kynurenine pathway in 





Table 1 Comparison of Tryptophan 2,3-dioxygenase (TDO) and Indoleamine 2,3-
dioxygenase (IDO) charactersitics – two key enzymes of the kynurenine pathway. Adapted 









Cofactors Molecular oxygen (O2) Superoxide anion 
Tissue distribution Liver Ubiquitous 
Function Degradation tryptophan Immune regulation 
 
TDO has very low affinity for TRP, therefore, the enzyme is only active when TRP 
levels exceed those required for protein and 5-HT synthesis [117]. The breakdown 
of TRP occurs in the liver to regulate TRP homeostasis [64]. This prevents the 
accumulation of TRP in the plasma and tissues to toxic levels. But TDO action is 
suppressed when IDO is induced during an inflammatory event [118]. The IDO 




during infections, pregnancy and inflammations [119-121]. Evidence suggests that 
the enzyme possesses peripheral and CNS immunosuppressive properties [122].  
Only 40% of CNS kynurenine is locally synthesised [123]. It is otherwise sourced 
from the general circulation, imported across the BBB via LAT1 [124]. As 
previously mentioned, this pathway provides both neuroprotective and neurotoxic 
effects [108-110, 125] in the CNS and is implicated with various pathologies, such 
as brain injuries, Alzheimer’s disease (AD), dementia and depression [126]. The 
over-activation of the kynurenine pathway was described in an AD mouse model 
brain, where TDO was found to be very highly expressed, thereby indicating a 
possible link with the neurodegenerative progression of the disease [127]. The 
kynurenine pathway has also been investigated as a potential new therapeutic option 
in the treatment of depression. Unfortunately, currently 20% of individuals with 
major depressive disorder (MDD) are resistant to available medicines [128]. Some 
propose that depression is linked with inflammation, as many autoimmune or 
inflammatory disease sufferers exhibit depression [129]. However, as the 
kynurenine pathway plays a role in peripheral inflammation it may be a potential 
target for further research into depression therapeutics [130]. 
Kynurenine metabolites play roles beyond those of inflammation, neuroprotection 
and neurotoxicity [108-110, 126]. The metabolite nicotinamide, formed in the liver, 
is a precursor for the enzyme nicotinamide adenine dinucleotide (NAD+), that is 
important for redox reactions [131]. Metabolites also have GI functions related to 




glutamate receptors affecting GI motility [63]. Its administration in dogs with 
mechanical colonic obstruction caused reduced GI motility in those animals [132].  
Kynurenine has also been correlated with body mass index (BMI) and obesity, but 
to date, no link has been firmly established with food intake or appetite regulation 
[83, 133]. In a recent human cohort, the analysis of the circulatory levels of 
kynurenine, as well as, the expression of key kynurenine pathway enzymes in the 
adipose tissues revealed a direct association with BMI [133].  
1.2.3 Serotonergic Pathway 
Serotonin (5-HT) is a monoamine neurotransmitter whose synthesis requires TRP 
as a precursor. Approximately 1-2% of total dietary TRP is utilised for 5-HT 
synthesis [68, 134]. Of that proportion, the majority is utilised via the peripheral 
system (approximately 95%) [135]. Most of the peripheral 5-HT is located within 
the enterochromaffin cells of the gut and in the serotonergic neurons of the enteric 
nervous system [135, 136]. The remaining proportion is dedicated to 5-HT 
synthesis within the CNS. With synthesis localised in both gut and the brain, 5-HT 
is involved in a range of physiological functions, including regulation of the GI 
system, mood and appetite [64, 71, 74, 75, 135]. 
The conversion of TRP to 5-HT in the brain is a two-step process (Figure 1.4). TRP 
first is hydroxylated into 5-hydroxytryptophan by tryptophan hydroxylase (TPH) – 
in the rate-limiting step [65, 137]. It then undergoes decarboxylation to form 5-HT 
using the enzyme aromatic acid decarboxylase [91]. Interestingly, the enzyme TPH 




therefore, 5-HT production is directly proportional to the amount of TRP crossing 
the BBB [138]. This has been demonstrated by the dose-dependent increase of 
central 5-HT in response to increases in dietary TRP or changes in the LNAA ratio 
[137, 139].  
 
Figure 1.4 The synthesis of serotonin and melatonin within the central nervous system 
from the biochemical precursor tryptophan. Adapted from Fernstrom, 2016 [70]. 
 
There are two different TPH isoforms [140]. The two distinct enzymes were first 
identified using tph1 knockout mouse models. It was initially assumed that all 5-
HT synthesis would be inhibited, but this was not the case as the knockouts 
displayed typical 5-HT activity as the tph2 gene was additionally present [140]. 
TPH1 is typically located in peripheral tissues, such as lung epithelial cells and 
predominantly in the enterochromaffin cells of the GI tract [63, 141-143]. 
Enterochromaffin intestinal cells synthesise and store 5-HT, activation of these cells 




physical, changes in intraluminal pressure due to movement of food or chemical, 
such as pH, glucose and bile acid [141, 144, 145]. Peripheral 5-HT can then 
stimulate the enteric nervous system to control GI motility and secretion [145]. 
Extracellular 5-HT can also directly act upon the CNS via the vagal afferents which 
project to the hindbrain [146]. 
TPH2 however is located in neurons, as well as, a small amount within the enteric 
nervous system, allowing both central and peripheral TPH2 function [135, 147]. 
Therefore, 5-HT can be synthesised not only in the gut, but also the CNS 
specifically by neurons in the raphe nucleus [148]. The raphe axons project to 
numerous brain regions [149, 150]. The rostral group sends axons to the forebrain 
e.g. cortex, amygdala (AMY), hippocampus and hypothalamus [151]. Many of 
these brain regions (especially, the hypothalamus) are involved in energy 
homeostasis and appetite regulation [152].  
These regions express various 5-HT receptor subtypes [152-154]. Since the first 
discovery of 5-HT receptors made in 1950’s in the ileum of guinea pigs [155], 
multiple 5-HT receptor subtypes have been identified e.g. 5-HT1A/5-HT1B/5-
HT1C/5-HT1D in the CNS as well as a peripheral 5-HT3 receptors [156]. Most of 
the 5-HT receptors are located within the nervous system (including substantia 
nigra, hippocampus, AMY, striatum and the frontal cortex) [151, 157, 158] as well 
as the GI tract [159].   
The reuptake of 5-HT occurs from the synaptic cleft back into the presynaptic 




hydroxylindoleacetic acid (5HIAA) by monoamine oxidase (MAO) and aldehyde 
dehydrogenase, then finally is excreted via the kidneys (Figure 1.4) [64]. 
From the point of the presumed role of TRP itself in appetite control, it is important 
to note that 5-HT administration reduces food intake via central and peripheral 
neuroendocrine pathways involving, among others, ghrelin and agouti-related 
protein (AGRP) [161]. 5-HT agonists suppress carbohydrate intake [162]. Changes 
in 5-HT synthesis or availability can affect food intake [152].  
1.2.3.1 Melatonin 
Melatonin entrains circadian rhythms, including those related to appetite [163]. Its 
synthesis relies on the pineal metabolism of 5-HT [66, 67]. The reaction is mediated 
by N-acetyltransferase to form N-acetylserotonin, and then, melatonin, via the 
enzyme hydroxyindol-O-methyltranferase (Figure 1.4) [164].  
Melatonin is synthesised during the dark phase [66, 164], but perturbations in 
plasma TRP availability can have long-term consequences on melatonin synthesis 
[165, 166].  In rats, 150mg/kg TRP generated an increase in circulating melatonin 
levels [167]. Dietary TRP fed to chickens in the light-phase caused enhanced 
melatonin synthesis for approximately 3 hours [166].  
In energy intake/metabolism studies, supplementation of non-diabetic rats with 
melatonin for four weeks showed a satiating effect [168]. Subcutaneous 
administration of melatonin, daily for 12 days in rats, lowered food consumption 
by 8.8% [169]. Human studies, however, have not yet provided a clear link between 




1.3 Key behavioural and physiological effects of tryptophan 
The physiological and behavioural effects of TRP arise from engaging a 
combination of the aforementioned peripheral and central processes. These TRP 
utilising pathways (e.g. kynurenine, serotonergic and melatonin pathways), when 
dysregulated, have been implicated in an array of complex disorders, including 
depression, sleep regression, anxiety, stress and social deficits [64, 71-75, 107, 126, 
163]. 
The two common approaches to study the involvement of TRP in behavioural or 
physiological processes involve either TRP loading/supplementation (methods that 
increase TRP availability) or acute tryptophan depletion (ATD) [65]. ATD involves 
suppression of TRP levels through, e.g., biochemical and dietary manipulation [172, 
173]. Over the past 50 years a substantial number of studies have been published 
that analyse the beneficial effects of TRP supplementation in humans and animals 
that are suffering from various behavioural and psychiatric conditions. 
1.3.1 Sleep 
In the sleep-wake cycle, rapid eye movement (REM) and non-REM sleep are 
crucial phases of sleep. The REM constitutes approximately 20-25%, and the 
remainder is non-REM sleep, which is often described as “deep” sleep [174, 175]. 
Within a typical sleep cycle (average period of 90-120 minutes), non-REM occurs 
first (90 minutes) and is made up of four stages which go from progressively light 
(stage one) to deep (stage four) sleep. Then a brief period of REM sleep occurs. 




the depth of non-REM sleep declining [69]. Any sleep pattern disruptions or 
disorders (i.e. insomnia) can have multiple health effects, including an increased 
risk of CVS, diabetes, and possibly, mood disorders [176].  
 
The direct influence of TRP ingestion on brain 5-HT levels suggests a potential role 
of TRP supplementation in enhancing sleep [71, 72]. 5-HT can be further 
metabolised in the pineal gland to the hormone melatonin, as described above in 
section 1.2.3.1 [70]. Administration of TRP enhances melatonin synthesis and its 
plasma concentration [167]. Treatments that decrease 5-HT concentration interrupt 
the sleep cycle, whereas sleep improvement is observed when 5-HT levels rise [73, 
177-179]. For example, healthy human volunteers receiving TRP (7.5g in milk 
drink) once daily for 10 days, showed an increase in both non-REM sleep and delta 
wave sleep, as well as a decrease in REM sleep, compared to those receiving the 
placebo [178].  
 
TRP supplementation in healthy participants with no sleep problems caused a mild 
hypnotic effect with reduced sleep latency [175, 180-184]. A range of oral doses 
seem effective in humans including 500 mg or 1 g mixed with 30 mg of the 
carbohydrate maltodextrin [180], 1.2 g or 2.4 g tablet [181], and 4 g tablet [182]. 
George and colleagues analysed sleep latency and sleepiness using the Standford 
Sleepiness Scale in 10 healthy humans. Participants were randomly assigned on 
separate days either placebo, 1.2 g or 2.4 g TRP orally. Both TRP doses were 
associated with reduced sleep latency, and the latency highly correlated with plasma 




sleepiness [181]. Doses between 1-5 g TRP given orally in mild insomniacs caused 
an improvement in sleep latency [175, 183, 184]. TRP loading, therefore, may have 
a beneficial effect on sleep patterns. 
The relationship between TRP and the regulation of the sleep-wake cycle extends 
upon critical CNS developmental phases in early childhood [185]. Breastmilk 
traditionally has higher levels of TRP than that of infant formulations [186, 187]. 
Heine and colleagues showed that the plasma TRP levels in breast-fed infants is 
typically higher than in those maintained on formula [185]. Fluctuations in TRP 
levels of breastmilk paralleled urinary levels of 6-sulfatoxymelatonin (a melatonin 
metabolite) in infants [188], suggesting a link between TRP intake and melatonin 
synthesis. Others have shown that maternal milk plays a role in the regulation of 
circadian rhythms in infants [189, 190]. In fact, Steinberg and collaborators used 
the measure of sleep latency and TRP plasma levels to assess the effect of TRP-
loading (0, 294, 588 or 882 µmol/L) on infant sleep. Sleep latency was defined as 
the time from the completion of the formula feed to the first stage of REM sleep. 
The highest TRP-fortified formula reduced sleep latency from 27.7 to 18.7 minutes 
compared to breastfed counterparts. Interestingly, the reduced sleep latency 
correlated with the plasma TRP:LNAA ratio [186].  
TRP depletion is oftentimes used to obtain information about the functional effects 
of lower brain 5-HT levels [65]. Nakamaru-Ogiso et al. induced 5-HT deficiency in 
rats by IP administration of the enzyme tryptophan side chain oxidase I (TSOI). 
This TRP-degrading enzyme reduces TRP plasma levels, by 1-2% within two hours.  




reduction compared to controls. In this rat model, both the circadian rhythmicity of 
sleep cycle and overall locomotor activity were reduced [173].  
TRP depletion to suppress 5-HT synthesis has also been used in human studies.  In 
12 healthy participants, TRP depletion was achieved through diet manipulation that 
led to altering the TRP:LNAA plasma ratio [191]. This influenced 5-HT level due 
to competitive transport of LNAA across the BBB via LAT1 (refer to section 1.2) 
[192]. The initial two nights established a baseline and on days three and four 
patients were given a low-protein diet. The last night of the study participants were 
given either a drink of amino acid mixture without TRP or one containing also 2.3 
g TRP (control group). Compared to controls, the TRP-depletion strategy caused 
an 85% reduction in plasma TRP levels. The use of sleep EEG revealed changes in 
sleep features, including, reduced REM sleep and increased awakeness [191]. The 
manipulation of the serotonergic system, via the depletion of its precursor, 
influences sleep disorders and patterns.  
1.3.2 Tryptophan and mood control 
Tryptophan (via the 5-HT circuit) has a profound influence on mood parameters 
and - consequently – on behaviours/physiological functions intertwined with mood. 
Therefore, it is not surprising that dysregulation within the TRP  5-HT 
biochemical pathway (including cellular and intercellular fate of 5-HT) underlies 
depression, anxiety, and obsessive-compulsive disorder (OCD) and their 
comorbidities (such as aberrant appetite, sleep and sociality, to name a few) [64, 65, 




serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCA)), that 
increase 5-HT signalling [65].  
As with sleep, ATD studies via dietary manipulation are useful in depression studies 
for assessing the direct effects of TRP deficiency [194, 195]. In humans, Delgado 
and colleagues (1989) analysed the behavioural effects of gradual dietary TRP 
depletion in healthy individuals. A 10-day TRP restriction diet was employed, with 
one group maintained on 700 mg/day and the other on 200 mg/day. Both of those 
diets produced a decline in total plasma TRP of 15-20% but no significant 
behavioural changes were reported [194]. A later study by the same group of 
investigators analysed ATD in depressed patients who were currently not receiving 
treatment. Rapid dietary depletion of TRP was induced in a double-blind, placebo-
controlled crossover study with one group receiving a 15-amino acid drink minus 
TRP, and the other, the same drink but inclusive of TRP. This caused a brief 
depression relapse in 67% of the TRP depletion group [195]. If TRP depletion 
induces depression, then it is expected that the opposite will occur with TRP loading 
[65].  
Indeed, the beneficial effects of increased TRP levels have been observed in 
patients suffering from mild to moderate depression [196, 197]. In a clinical trial of 
115 depressed patients a 12-week double-blind study assessed the effectiveness of 
TRP compared to a placebo. All participants received the placebo for the first week 
– then the experimental group received 1 g of TRP, three times daily for up to 12 




with the Hamilton Depression Scale [197]. TRP supplementation in healthy 
individuals shows little to no effect on mood [65].  
TRP supplementation in animal depression models has been controversial with 
some reporting no effect and others reporting mild improvement [172, 198]. Brown 
and colleagues (1998) demonstrated that when rats were orally gavaged with TRP-
containing amino acid mixture, an amino acid load without TRP or water, there 
were no acute differences in behaviour between the groups in an operant schedule 
of differential reinforcement (DRL) and locomotor activity [172], both of which are 
changed after central 5-HT [199-203]. On the other hand, Blokland and associates 
utilised a moderate TRP depletion animal model to reduce central 5-HT levels. Rats 
were orally infused with either a TRP-positive amino acid load or a TRP-negative 
amino acid load. Five hours after infusion, the home cage emergence test (HCET) 
was performed, in which the animal was placed in its home cage in the arena with 
the lid removed and latency till the animal leaves its home cage was recorded. The 
TRP depleted rats exhibited increased latency indicating more anxiety-related 
behaviour [204]. Other methodologies used to assess depressive-like behaviours 
include sucrose preference test, open field test (OFT) and forced swim test (FST). 
Typically, depressed rats exhibit reduced sucrose intake; reduced distance travelled 
and increased immobility in OFT; and a decreased latency to immobility during 
FST [205]. In sub-chronic TRP depletion (SCTD) studies, Sprague-Dawley rats 
were supplemented with low TRP diets (0.04%) compared to control (0.2% TRP) 
for either 0, 7 or 14 days, followed by assessment of depression-like behaviours via 
FST. Those on chronic sub-TRP showed increased floating time and reduced 




This study also notes an increase in the metabolite kynurenine, suggesting a role for 
the kynurenine pathway in depression [198]. 
Kynurenine pathway metabolites exhibit various neuroprotective and neurotoxic 
effects [108-110], implicated in various pathologies, including depression [126]. 
For example, during pregnancy, immune-inflammatory activity generates more 
kynurenine pathway metabolites [130, 206-208]. Conversely, high levels of 
kynurenine pathway metabolites (e.g. kynurenic acid and quinolinic acid) have 
neuroregulatory effects [209]. 
1.4 Tryptophan and appetite regulation: a possible mediator of 
satiety 
Evidence providing support for a role of TRP in termination of food intake, is still 
very limited [23, 28, 29]. Daily dietary supplementation of TRP at 3.0 g/kg 
bodyweight reduced food intake in ad libitum-fed rats by approximately 25% and 
it led to an overall reduction in bodyweight. This was the result of alterations in 
meal pattern – most noticeably increases in meal size, intermeal intervals, meal time 
and a decrease in meal number [29].  
In 1992, Ng and Anderson infused TRP in rats maintained on a 12-h/day availability 
schedule of both standard and high-carbohydrate (protein-free) diet. These 
intragastric infusions (200-600 mg/kg TRP) induced a decrease in episodic 
consumption [28]. Jordi and colleagues (2013) also utilised the intragastric route of 
administration. Food-deprived rats received isomolar doses (6.7 mmol/kg) of one 




demonstrated a 25% reduction in chow intake, when compared to the vehicle. TRP 
was ranked as the 4th most potent anorexigen when compared to the other amino 
acids. Unfortunately, statistical significance was not achieved when corrected for 
multiple comparisons [23]. 
Importantly in that study, c-Fos immunoreactivity (commonly used as a measure of 
neuronal activation [210]) analysis revealed alterations in neuronal activity 
following exposure to anorexigenic amino acids (albeit, due to the lack of 
significance, TRP was excluded from the c-Fos mapping experiment). Increase in 
the number of Fos positive nuclear profiles in the brainstem, particularly in the 
dorsal vagal complex (DVC) components, including, the NTS and the AP, 
suggested a likely involvement of vagal afferents and potential influence of 
biochemical changes in plasma (since the AP is virtually devoid of the BBB) [23]. 
Axons from the DVC innervate other brain sites, notably, the hypothalamus [211].  
1.5 Mechanisms controlling food intake: basic information 
Energy balance, crucial for the survival of an organism and for the maintenance of 
fundamental physiological functions, relies on mechanisms that ensure that energy 
intake equals or exceeds energy expenditure. In the obesogenic environment, 
excessive consumption maintained for a long-time period can cause weight gain 
and obesity [6-9]. Feeding regulation is critical to enable an organism to meet both 
energy and nutrient requirements, without being at risk of jeopardising internal 
milieu (e.g., through excessive stomach distension, presence of toxins or high 
osmotic load) [212, 213]. These integrated regulatory mechanisms are required to 




internal (e.g., neurohormones, osmolality, food derived signals, chemo- and 
mechanoreceptors) and external environment (e.g., circadian rhythms and social 
behaviours). Thus, the control of food intake is an interplay between both the 
homeostatic (that protects internal milieu) and non-homeostatic (e.g. hedonic) 
systems [11]. 
Satiation is the process relating to the termination of food consumption due to a 
feeling of fullness, ensuring that maximum gastric capacity is not breached [52, 
213]. There are mechanoreceptors in the stomach itself that sense gastric distension 
and relay this information via the vagal afferents to the hindbrain [214]. Upon 
ingestion of protein, satiety-inducing hormones (e.g. CCK, GLP-1, and PYY) are 
released from the enteroendocrine cells of the GI tract. These can directly act 
centrally by crossing the BBB from the general circulation or indirectly via vagal 
afferents [47]. The hindbrain structures relay information to the hypothalamus 
including peripheral signals, such as neural (vagal), hormonal (e.g. CCK) and 
biochemical (e.g. plasma ion/toxins) inputs [47, 52, 214]. These relay centres 
include the DVC which encompasses the nucleus of the NTS, the dorsal motor 
nucleus of the vagus (DMNV) and AP [47, 211].  
The hypothalamic network integrates numerous endocrine signals (Figure 1.5), for 
example, leptin and insulin – leptin reports on the levels of energy stored in fat 
[215]. Decreased leptin signalling from adipocytes promotes increased caloric 
intake and fat accumulation [216-218]. Leptin modulates intake via leptin receptors 
expressed in the hypothalamus e.g., arcuate nucleus (ARC), supraoptic nucleus 




and the lateral hypothalamic area (LH) [216]. The ARC contains vast populations 
of neurons expressing orexigenic and anorexigenic peptides. These neurons are 
capable of sensing energy related signals and activate feeding-relevant pathways in 
order to generate behavioural changes conducive to maintaining energy balance. 
For example, ARC neurons are stimulated by both leptin and insulin, express 
proopiomelacortin (POMC), which – after posttranslational processing – gives rise 
to alpha-melanocyte-stimulating hormone (α-MSH) [52, 216]. α-MSH is released 
in the PVN where it binds the melanocortin-4 receptors to reduce food intake [219-
221]. Conversely, ARC orexigenic neurons express neuropeptide Y (NPY) and 
AGRP. Activity of these cells is inhibited by leptin [52, 216]. Orexigenic action of 
AGRP involves competitive antagonism of PVN melanocortin-4 receptors, whereas 
NPY influences PVN activity to enhance appetite via interactions with its Y1/Y5 
receptors [52, 216]. To add to this complexity of appetite stimulating processes 
elicited by ARC NPY/AGRP neurons is the inhibition of POMC neurons by co-
release of gamma-aminobutyric acid (GABA) [222, 223]. Hence, aside from 
activating relevant PVN target cells that promote appetite, NPY/AGRP neurons 
simultaneously block activation of the ARC POMC cells, thereby further ensuring 
hyperphagia by reducing satiety [216].  
Appetite regulation is not simply dependent on energy homeostasis; food ingestion 
is greatly motivated by palatable foods, even when such diets are overabundant and 
readily available (hence, energy deficit is not the main drive to eat). This has been 
reliably shown in studies involving a cafeteria diet paradigm, in which animals 
presented with a choice of nutritionally adequate yet bland versus highly palatable 




reward circuitry promotes hedonic feeding despite aversive conditions such as foot 
shocks or extreme cold, even when animals are not deprived [225, 226]. 
 
 
Figure 1.5 A simplified schematic of food intake control by the central nervous 
system with a focus on anorexigenic peripheral signals. Cholecystokinin (CCK) is 
released from the gastrointestinal (GI) tract and acts upon nucleus of the solitary 
tract (NTS) via vagal afferents. The adiposity signalling hormone leptin affects 
neuropeptide Y (NPY) and agouti-related protein (AGRP) expressing neurons as 
well as proopiomelanocortin (POMC) expressing neurons located in the arcuate 
nucleus (ARC) of the hypothalamus. POMC is processed into alpha-melanocyte-
stimulating hormone (α-MSH) which binds to melanocortin receptors (MCRs) in the 
paraventricular nucleus (PVN) to suppress appetite. NPY/AGRP neurons inhibit 
POMC production via gamma-aminobutyric acid (GABA) co-release. They also act 
on the PVN with AGRP being a competitive antagonist of MCRs and NPY 





A multitude of reward-related pre- and post-absorptive peripheral processes [227] 
affect activation of various brain regions in the mesocorticolimbic, hypothalamic 
and midbrain circuitry and stimulate neural processing conducive to reinforcement 
of the rewarding aspect of food [228, 229]. Consumption of palatable food enhances 
neuronal activity in reward-related areas and changes gene expression of reward-
related genes, especially those related to the dopamine, opioid and endocannabinoid 
systems [230].  
Two brain regions crucial for reward processing are: the ventral tegmental area 
(VTA) and nucleus accumbens (Acb), and they are part of a network that relies on 
opioid, dopamine, 5-HT, and endocannabinoid signalling [231-237]. Dopaminergic 
activity is associated with the motivational aspect of reward [238]. In rats, 
consumption of 0.3M sucrose increased dopamine metabolite levels in the Acb by 
three-fold compared to the consumption of water [239]. The concentration-
dependent effect of sucrose on dopamine levels in the Acb have been shown in rats 
given sucrose concentrations (0.03M, 0.1M and 0.3M) via a gastric cannula 
(bypassing taste receptors) [240]. Opioids are involved with processing the hedonic 
value or palatability aspects of the diet [241, 242]. Opioid receptor agonists promote 
the consumption of palatable food by increasing their hedonic value, whereas 
antagonists have the opposite effect [243, 244]. 
1.6 Role of oxytocin in appetite regulation 
The last decade of feeding research has brought a tremendous leap in our 
understanding of neuropeptidergic systems that bridge control of ingestive 




crucial sets of discoveries pertains to the neurohormone oxytocin (OT), a nine-
amino acid anorexigenic peptide synthesised mainly in the hypothalamic PVN and 
SON [252-256]. OT cells reciprocally communicate with DVC neurons (Figure 1.6), 
thus serving as a key element of pathways that ensure integration of peripheral 
information relevant to the energy/feeding status of the organism [245-247].  
While the majority of magnocellular OT neurons in the PVN and SON terminate in 
the neurohypophysis, parvocellular PVN OT cells target the aforementioned 
brainstem areas (thus being a part of the ‘homeostatic’ circuit) as well as sites 
involved in reward [212, 248-251]. The combination of the two general CNS 
projection targets serves as a neuroanatomical foundation implicating OT in 
mediation of satiety to protect internal milieu and to decrease feeding-derived 
hedonics [212]. Early experiments showed that lesioning of the PVN in rats disturbs 
the PVN to hindbrain projections and resulted in greater food consumption and 
body weight [252-254].  
The release of OT and enhanced OT neuronal activity have been observed to 
coincide with termination of feeding [255-258]. Arletti et al. demonstrated that ICV 
OT greatly decreased chow intake in deprived rats [256]. Ho and colleagues 
determined that activation of NTS neurons mediated this effect of OT [259], 
strengthening the hypothesis for the role of the hindbrain in OT-driven feeding 
inhibition. 
Both hyperphagia and obesity have been observed in mutations that result in 
abnormalities in PVN neuronal development, leading to OT deficiencies [260-262]. 




lacks sim-1, a transcription factor responsible for the development of the PVN. 
Hyperphagic obesity was observed in these individuals, and it was later reversed by 




Figure 1.6 Central functional OT pathways with a focus on those involved in food 
intake regulation. The parvocellular OT neurons within the PVN project to the 
brainstem particularly the NTS, AP, and DMNV, all known to be involved in appetite 
regulation. The magnocellular OT neurons project to the pituitary gland where OT 
gets released into the general circulation. OT is also involved in anorexigenic inputs 
from the periphery, for example, GI tract distension and osmolality of the blood. 
Other feeding related sites known to contain OT neurons and receptors include those 
involved in reward (ventral tegmental area (VTA), nucleus accumbens (Acb), bed 
nucleus of the stria terminalis (BST)), energy homeostasis (ventromedial 






Changes in other calorie-independent ‘homeostatic’ parameters induce OT 
neuronal activation and termination of feeding [212]. For example, excessive 
stomach distension and elevated plasma osmolality (ion imbalance due to salt 
loading) lead to OT release [264-266]. OT also inhibits intake of toxin-tainted food 
and generates long-term avoidance of those by acting through both the AMY and 
brainstem [267]. 
Whilst the role of OT in energy homeostasis is now widely recognised, the notion 
for the role of central OT in feeding reward and macronutrient preference has only 
begun to emerge over the past several years [212, 268-270]. The OT receptor is 
highly expressed in brain regions associated with food reward, particularly the VTA 
and Acb, with PVN OT neurons innervating both of these key regions [248-251]. 
In fact, OT terminals have been found near mesolimbic neurons where they form 
both somatic and axodendritic synapses [248, 249].  
The cross-link between the OT and the reward system appears reciprocal [245-247]. 
The existence of opioid receptors on hypothalamic OT neurons provides evidence 
for this relationship, and so does the fact that orexigenic opioid agonists silence 
activation of OT cells [271-274]. This interaction also appears to involve non-
feeding rewards e.g. social or reproductive behaviour and alcohol/drug intake [212, 
268]. Cocaine usage in female rats altered OT receptor binding density in the bed 
nucleus of the stria terminalis (BNST) [275]. The intraparenchymal infusion of OT 
removes conditioned place preference induced by methamphetamine and ethanol, 
as well as, overcoming methamphetamine seeking behaviour [276-278]. Female 




Knockout models further support the role of OT in feeding reward. Amico and et 
al. demonstrated that the deletion of the OT gene resulted in excessive intake of 
palatable sucrose [269]. This effect was independent of the 24-hour light cycle, with 
high sucrose intake maintained over both light and dark phases [270]. When the 
OT-null knockouts were provided a two-choice test between water and sucrose, 
animals consistently displayed a stronger preference for the sucrose solution. They 
also drank more of a highly palatable and non-caloric saccharin solution [280]. 
Increased consumption of this particular solution by OT-null mice provides 
evidence for OTs role in hedonic, rather than homeostatic, feeding. 
To follow up on the knockout findings, rodent injection studies in wild-type animals 
utilising the BBB penetrant OT antagonist, L-368,899, in both choice and no-choice 
feeding paradigms were performed [281]. These have consistently found elevated 
carbohydrate intake, with no effect on fat consumption [282, 283]. Mullis and 
colleagues demonstrated that direct VTA OT administration reduced reward-driven 
sucrose consumption which was reversible with pre-treatment of L-368,899. They 
also identified that a blockade of the OT receptor in the VTA leads to 
overconsumption of sugar [284]. OT injection into the Acb core (but not the shell) 
reduced intake of palatable carbohydrates and, to a greater extent, the intake of 
saccharin [285]. Some evidence also exists for the role of OT in fat intake regulation. 
Zhang and colleagues provided infusions of OT receptor antagonist into the third 
ventricle of mice fed a high-fat diet. They observed increased food intake and body 




Lastly, consideration needs to be made for the fact that OT influences a multitude 
of functions that are intertwined with ingestive behaviour. Consequently, the 
orexigenic response to L-368,899, depends on the place within social hierarchy in 
group-fed mice [288], whereas individually housed mice consistently increased 
sugar intake following administration of L-368,899 [282, 283, 289].   
Despite the great interest in OT’s involvement in feeding termination, to date a 
possible relationship between this key hypothalamic satiety mediator that is part of 
both homeostatic and hedonic pathways and a presumably anorexigenic amino acid, 
TRP, has not been investigated. It leaves a significant gap in our knowledge of both 
how TRP affects consumption and whether circuits encompassing OT neurons can 
respond to changes in TRP availability. Therefore, I hypothesised that TRP will 
exhibit an anorexigenic effect and that this TRP-induced hypophagia will be 





The overarching aim of this doctoral research was to examine whether 
tryptophan suppresses food intake and whether this potential anorexigenic 
effect is mediated via central circuits that regulate consumption. This project, 
utilising mice and rats as model organisms, encompassed three specific aims:  
Specific Aim 1: To determine whether intragastric administration of TRP affects 
intake of tastants that differ in energy density and in palatability (palatable, non-
caloric and caloric). To examine whether the changes in appetite observed after a 
TRP intragastric preload are accompanied by changes in neuronal activation (c-Fos), 
in brain areas that regulate food intake (Chapter 2). 
Specific Aim 2: To determine whether the IP administration of TRP (thereby, 
preventing the direct action of TRP on gut mucosa) affects intake of tastants that 
differ in energy density and in palatability (palatable, non-caloric and caloric). To 
examine whether the changes in appetite observed after a TRP IP preload are 
accompanied by changes in neuronal activation (c-Fos), in brain areas that regulate 
food intake (Chapter 3). 
Specific Aim 3: To determine whether the anorexigenic effect of TRP is 
accompanied by changes in OT neuronal activation. To assess whether OT receptor 
blockade with an OT antagonist alleviates the anorexigenic effect of TRP on 
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2 Effects of intragastric preloads of L-tryptophan on 
ingestive behaviour: a link with key central 
mechanisms that regulate consumption 
2.1 Abstract 
Human and laboratory animal studies suggest that dietary supplementation of a free 
essential amino acid, L-tryptophan (TRP), reduces food intake. It is unclear whether 
an acute gastric preload of TRP decreases consumption and whether central 
mechanisms underlie TRP-driven hypophagia. I examined the effect of TRP 
administered via intragastric gavage on both energy- and palatability-induced 
feeding in mice. Then sought to identify central mechanisms that mediate the 
anorexigenic effect of TRP. These effects on the consumption of energy-dense and 
energy-dilute tastants were established in mice stimulated to eat by energy 
deprivation or palatability. A conditioned taste aversion (CTA) paradigm was used 
to assess whether hypophagia is unrelated to sickness. c-Fos immunohistochemistry 
was employed to detect TRP-induced activation of feeding-related brain sites 
associated with feeding-related circuitry. TRP reduced intake of energy-dense 
standard chow in deprived animals and energy-dense palatable chow in sated mice. 
A CTA was not induced by anorexigenic doses of TRP. Intragastric TRP failed to 
affect intake of palatable yet calorie-dilute or noncaloric solutions (10% sucrose, 
4.1% Intralipid or 0.1% saccharin) even for TRP doses that decreased water intake 
in thirsty mice. Fos immunoreactivity analysis revealed that TRP increases 




hypothalamus. In sum, intragastric TRP preloads decrease food and water intake, 
and that TRP-induced hypophagia is partially mediated via central satiety-related 





Elevated dietary protein reduces food intake by affecting oral, postoral and 
postabsorptive mechanisms, including consumption-related reward, satiation, and 
energy metabolism [1-3]. While the gross protein value greatly affects energy 
balance, it has been suggested that in the process of ensuring that precise nutritional 
requirements are met - individual amino acids may play a role in regulating a drive 
to ingest food [4]. The need to control food intake is particularly pressing in relation 
to the essential amino acids, i.e., those that cannot be synthesised by the mammalian 
organism [5]. Thus far, an anorexigenic effect has been previously reported 
following the administration of individual amino acids, for example, L-leucine, L-
arginine, L-lysine, L-cysteine and L-glutamic acid [6-12].  
One such amino acid is L-tryptophan (TRP) [13, 14]. TRP interacts indirectly via 
ubiquitous G-protein coupled receptors [15]. Also, it enters the general circulation 
directly from the GI tract via transporters in a dose-dependent manner within 
minutes after intragastric delivery [16-18], and ultimately crosses the BBB thereby 
directly affecting CNS neurons [13, 19]. The LAT1 transporter is the main amino 
acid transporter in the BBB and is responsible for the transport predominantly of 
essential amino acids (including TRP) from the luminal side [20-22]. Thus, the 
physiological and behavioural effects of dietary TRP stem from engaging a 
combination of peripheral and central processes.  
In studies focusing on the regulation of feeding behaviour, TRP has been proposed 
to promote hypophagia; however, the data remain somewhat inconsistent. For 




food intake in ad libitum-fed rats by ca 25% [16]. Intragastrically administered 200-
600 mg/kg TRP has been found to cause a similar decrease in consumption in rats 
maintained on the 12-h/day availability schedule of both standard and high-
carbohydrate (protein-free) food [17]. More recently, the intraduodenal infusion of 
low-caloric TRP loads (either 0.075 or 0.15 kcal/min for 90 minutes) in humans, 
suppressed acute energy intake and increased fullness after the post-infusion 
standardised buffet meal [23]. On the other hand, Jordi et al. (2013) reported only 
an insignificant reduction in chow intake in rats treated with intragastric TRP after 
12 h of fasting, although the experiment may have been statistically underpowered 
[6].  
The current set of studies was focused on providing more systematic evidence 
related to the presumed role of intragastric TRP in feeding control and the 
involvement of central circuitry in mediating TRP-induced hypophagia. The 
intragastric route for administration was selected as it most resembles normal 
dietary intake of amino acids, thereby allowing the normal uptake of amino acids 
within the GI tract, whilst bypassing the taste receptors [17]. 
Using the mouse model, I examined the acute effects of intragastric TRP preload 
on deprivation-induced intake of energy-dense chow as well as on the intake of 
energy-dense palatable chow in non-deprived animals. A CTA paradigm was 
employed to provide evidence that TRP-driven anorexia does not arise from 
sickness/malaise [24]. Then, I determined whether TRP can diminish palatability-
driven consumption of calorie-dilute solutions, and whether the anorexigenic effect 




Furthermore, I expanded on the aforementioned evidence indicating the 
involvement of the brain in mediating anorexic properties of amino acids by treating 
mice with a predetermined hypophagic dose of TRP and mapping c-Fos 
immunoreactivity (c-Fos-IR, a marker of neuronal activation [25]) in central sites 
known to control appetite [26].  
2.3 Materials and methods 
2.3.1 Animals and intragastric administration 
Adult male (12 weeks) C57BL/6 mice were housed individually under a 12:12 h 
light/dark cycle (lights on at 07:00) and maintained at a controlled temperature of 
22˚C. The mice had ad libitum access to tap water and standard laboratory chow 
(Specialty Diets, Australia) unless specified otherwise. All procedures received 
prior approval from the University of Waikato animal ethics committee. 
Animals were acclimatised to the oral gavage procedure prior to the studies. 
Individuals either received an equal volume (0.2ml) of water or L-TRP solution 
(Sigma, UK). 
2.3.2 Consummatory behaviour studies 
2.3.2.1 Effect of TRP on deprivation-induced intake of standard chow 
Animals were divided into four groups (n=7-9/group) and were food-deprived 
overnight. They were then given either TRP (600, 1200 or 1800 mg/kg TRP in 
0.2ml water) or equal volume of vehicle (water) intragastrically 20 minutes prior to 




study by Jordi et al. (2013) on amino acid intragastric administration, in which 6.7 
mmol/kg molar (equivalent to 1200 mg/kg TRP) was tested as the standard dose for 
all amino acids [6]. Chow intake was measured at 1 and 4 h. Water was available 
at all times. To control for the effect of amino acid-derived osmolality, in a separate 
experiment, alanine intragastric infusions (6.7 mmol/kg, which is a molar 
equivalent to 1200 mg/kg TRP; the same volume was infused) was used versus 
water and saw no effect on deprivation-induced food intake (Figure 2.2 D).  
2.3.2.2 Effect of TRP on the intake of palatable chow in non-deprived mice 
In order to examine whether TRP decreases the consumption of palatable solid food 
in non-deprived animals, by following our previously published protocol ([27, 28]), 
then gave mice 2-h access to palatable goat milk-enriched chow (3.5 kcal/g; Plant 
& Food Research, New Zealand) at 10:00. Twenty minutes earlier, the animals 
received TRP (600 mg/kg or 1200 mg/kg) or vehicle (n=6/group). Standard chow 
was removed from the cages from the time of intragastric infusion until the end of 
the 2-h period of palatable diet availability. The animals had had previous episodic 
exposure to this chow to avoid neophobia. 
2.3.2.3 Effect of TRP on the episodic intake of palatable solutions 
The paradigm described herein was based on the protocol used in our earlier studies 
[28-30]. The palatable solution tests were done in separate crossover tests using 
different mice. Three cohorts of mice were accustomed to receiving 10% sucrose, 
0.1% saccharin or 4.1% Intralipid palatable solutions for 2 h/day on 2 days (10:00-
12:00) prior to the experiment to avoid neophobia (sucrose study: n=7-8/group; 




were isocaloric. On the experimental day, animals were given TRP (saccharin and 
Intralipid: 600 mg/kg and 1200 mg/kg TRP; sucrose: 1200 mg/kg and 1800 mg/kg 
TRP) or vehicle 20 minutes before gaining access to the solutions. Chow and water 
were removed from the cages from the time of intragastric infusion until the end of 
the 2-h testing period. Palatable solution intake was measured after 2 h by weighing 
bottles. 
2.3.2.4 Effect of TRP on water intake in water-deprived rats 
Overnight water-deprived mice were treated with intragastric TRP (600 mg/kg or 
1200 mg/kg) or vehicle (n=6/group) 20 minutes prior to regaining access to water. 
At 10:00, water bottles were returned to the cages and intake was measured 2 h 
post-injection. Chow was removed from hoppers from the time of intragastric 
infusion until the end of the 2-h water intake test. 
2.3.3 Effect of TRP on the acquisition of a CTA 
The standard CTA protocol was applied utilising a novel flavoured solution (see 
e.g., [30]). Mice had water taken away 16 h before their first exposure to a novel 
strawberry-flavoured KoolAid solution (2 h; from 10:00 to 12:00; Kraft Foods; 
prepared fresh according to the manufacturer’s instructions) followed by 
intragastric infusion of 1200 mg/kg TRP (the dose that reliably caused hypophagia 
in all of the aforementioned models in which TRP was found to be anorexigenic) 
or saline (n=7/group). One hour after the treatment, water was returned to the cages 
to avoid dehydration. Two days later, animals were deprived of water again and, 
after 18 h, they were subjected to a 2-h two-bottle test in which a choice between 




KoolAid were measured after 2 h, and preference was expressed as the percentage 
of KoolAid intake in the total volume of consumed fluid (KoolAid+water). 
2.3.4 Immunohistochemistry 
The mice received either a single intragastric infusion of 1200 mg/kg TRP (the dose 
that reliably caused hypophagia in all of the aforementioned models in which TRP 
was found to be anorexigenic) or water vehicle (n=6/group for single Fos staining). 
Immediately after the treatment, which was performed between 10:00-11:00, both 
food and water were removed from the cages. Animals were anaesthetised (35% 
urethane) and perfused with saline (20mL) followed by 50mL of 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) between 80-90 
minutes after TRP/vehicle infusions. Brains were removed and postfixed overnight 
in PFA at 4˚C. Coronal 60 – um vibratome (Leica, Germany) sections were 
processed for c-Fos immunostaining. The tissue was treated for 10 minutes in 3% 
H2O2 in 10% methanol (in Tris-buffered saline (TBS); pH 7.4) and incubated 
overnight at 4˚C in the rabbit anti-Fos antibody (1:1400; Synaptic Systems, 
Goettingen, Germany). The next day, sections were incubated for 1 h in the 
secondary goat-anti-rabbit antibody (1:400; Vector Laboratories, USA), then rinsed 
in the buffer before incubating in the avidin-biotin complex (1 h; Vector 
Laboratories). Peroxidase was visualised with 0.05% DAB, 0.01 % H2O2 and 0.2% 
nickel sulphate (Sigma, USA). All incubations were conducted in a mixture of 0.25% 
gelatin and 0.5% Triton X-100 (Sigma, USA) in TBS. Intermediate rinsing was 
performed with TBS. Sections were mounted on gelatinised slides, dried, 
dehydrated in ascending concentrations of ethanol, soaked in xylene and embedded 




counted bilaterally in all regions of interest (4-5 sections containing a given site per 
animal) by a person blinded to the experimental group allocation. Densities of c-
Fos positive nuclei (per mm2) were averaged per mouse and then per group. 
2.3.5 Statistical analyses 
Data from all consummatory behaviour studies utilising single TRP administration 
were processed with a Student’s t-test (two-group comparisons) or a one-way 
ANOVA followed by Dunnet’s post-hoc analysis (multiple-group comparisons). 
Correction for multiple comparisons was applied. Values are presented as means ± 
S.E.M and they were deemed significantly different when p≤0.05. 
2.4 Results 
Intragastric administration of TRP caused a statistically significant reduction in the 
amount of standard chow eaten after overnight energy deprivation (Figure 2.1 A). 
This decrease was evident for 1200 and 1800 mg/kg doses at 1 h (F(3, 26)=12.96; 
1200 mg/kg P=0.004; 1800 mg/kg, P=0.004) and 4 h (F(3, 26)=13.6; 1200 mg/kg 
P=0.002; 1800 mg/kg, P=0.012) of re-feeding, but there was no effect at 24 h. In 
sated mice that were stimulated to eat by brief, 2-h, access to palatable chow, not 
only 1200 mg/kg TRP, but also a 600-mg/kg dose decreased consumption (F(2, 
15)=5.24; P=0.028 and 0.022, respectively; Figure 2.1 B). Importantly, 1200 mg/kg 
TRP did not promote the development of a CTA to a novel KoolAid solution 
(Figure 2.2 A). Alanine, used in this study as an osmotic control, did not cause a 




1200 mg/kg TRP significantly reduced water intake induced by water deprivation 
(F(2, 14)=7.73; P=0.003; Figure 2.3 A). TRP failed to affect consumption of 
palatable non-caloric saccharin (Figure 2.3 B) and calorie-dilute (0.4 kcal/g) 10% 
sucrose and 4.1% Intralipid solutions in non-deprived mice (Figure 2.4 A, B). Even 
a dose as high as 1800 mg/kg, TRP did not modify sucrose solution intake.  
Administration of TRP at 1200 mg/kg, the dose that caused the most reliable 
anorexigenic effect in all consumption paradigms in which TRP generated a 
statistically significant change, affected c-Fos immunoreactivity in 8 out of 13 
specific brain regions involved in the regulation of ingestive behaviour (Figure 2.5 
A). An increase was observed in the dorsal medial nucleus of the vagus (DMNV; 
P=0.049) and nucleus of the solitary tract (NTS; P=0.006) in the brainstem 
(Figure 2.6 C), in the hypothalamic PVN (P=0.001), SON (P=0.024) (Figure 2.5 B, 
C) and dorsomedial (DMH; P=0.001) nuclei (Figure 2.6 A), as well as in the central 
nucleus of the amygdala (CeA; P=0.001) (Figure 2.6 B). A decrease in the density 
of c-Fos positive was noted in the core and shell subdivisions of the nucleus 






Figure 2.1 The effect of intragastric TRP preload on (A) deprivation-induced intake 
of standard chow at 1h and 4 h of re-feeding; and (B) intake of palatable chow in 
non-deprived animals. Doses are in mg/kg BW. Water served as vehicle (0 mg). * - 








Figure 2.2 The effect of intragastric TRP preload on (A) acquisition of a conditioned 
taste aversion (CTA) to a novel KoolAid solution (expressed as a percentage of 
KoolAid intake in the total KoolAid+water consumption assessed in a two-bottle 
choice test performed 48 h after the initial exposure to KoolAid). Panel (B) shows 
deprivation-induced chow intake after intragastric alanine (as an osmotic control for 
TRP). Doses are in mg/kg BW. Water served as vehicle (0 mg). * - P≤0.05; ** - 






Figure 2.3 The effect of intragastric TRP preload on (A) water intake induced 
by water deprivation; and (B) palatability-induced intake of a 0.1% saccharin 
solution. TRP doses are in mg/kg BW. Water served as vehicle (0 mg). * - 







Figure 2.4  The effect of intragastric TRP preload on (C) palatability-induced intake 
of a 10% sucrose solution, and (D) palatability-induced intake of a 4.1% Intralipid 










Figure 2.5 c-Fos immunoreactivity in select feeding-related brain sites following 
intragastric administration of 1200 mg/kg TRP versus vehicle. The graph (A) shows 
densities of Fos positive nuclear profiles per mm2 of each area of interest. 
Photomicrographs (B-C) depict c-Fos in some brain areas in which a significant 
change was noted (control: left panels; TRP: right panel). 3v – third ventricle; 4v – 
fourth ventricle; aca – anterior commissure; AcbC – nucleus accumbens core; AcbS 
– nucleus accumbens shell; AP – area postrema; ARC – arcuate nucleus; BLA – 
basolateral amygdala; CeA – central nucleus of the amygdala; DMH – dorsomedial 
hypothalamic nucleus; DMNV – dorsal motor nucleus of the vagus; LH – lateral 
hypothalamus; NTS – nucleus of the solitary tract; otr – optic tract; PVN – 
paraventricular hypothalamic nucleus; SON – supraoptic nucleus; VMH – 






Figure 2.6 c-Fos immunoreactivity in select feeding-related brain sites following 
intragastric administration of 1200 mg/kg TRP versus vehicle. Photomicrographs 
(A-D) depict c-Fos in brain areas in which a significant change was noted (control: 
left panels; TRP: right panel). 3v – third ventricle; 4v – fourth ventricle; aca – 
anterior commissure; AcbC – nucleus accumbens core; AcbS – nucleus accumbens 
shell; CeA – central nucleus of the amygdala; DMH – dorsomedial hypothalamic 
nucleus; DMNV – dorsal motor nucleus of the vagus; NTS – nucleus of the solitary 





Enrichment of food with protein promotes a decrease in consumption, as 
consistently observed in human and laboratory animal studies [1-3]. A variety of 
factors have been implicated in this anorexigenic effect. High-protein diets tend to 
have diminished palatability, resulting in a reduced drive for consumption. Protein 
intake triggers endocrine processes conducive to early satiation, such as the release 
of GLP-1 and PYY, as reported for both humans and mice [31, 32]. A reduction in 
appetite occurs during protein consumption, but also during a subsequent meal, 
which reflects sustained satiety in protein-derived hypophagia [33]. The 
epidemiological potential of mechanisms mediating protein-derived satiety for 
overcoming the current obesity ‘epidemic’, has been increasingly recognised over 
the past years.  
Research has discovered that not only complex proteins, but specific individual 
amino acids, can act as potent anorexigens e.g., L-leucine [9, 12], L-cysteine [8], 
L-arginine, L-lysine and L-glutamic acid [6, 7]. Unlike those aforementioned amino 
acids, prior data on feeding-related effects of TRP are inconsistent, with some 
authors reporting moderate hypophagia [16, 17], whereas others failing to observe 
a decrease in appetite in rats [6]. The current findings provide evidence for the role 
of TRP in the regulation of consumption suggesting that a TRP preload reduces 
ingestive behaviour and this effect is potentially mediated via central appetite-
related circuits. 
In line with the proposed role in promoting satiation thereby reducing meal size 




the baseline levels during the first hour of re-feeding, and the hypophagic effect 
continued at 4 h. The intraduodenal infusion of low-caloric TRP loads (either 0.075 
or 0.15 kcal/min for 90 minutes) in humans, demonstrated a comparable 
suppression of episodic energy intake and increased fullness after the post-infusion 
standardised buffet meal [23]. In deprived animals, motivated to eat by hunger, 
1200 mg/kg TRP was necessary to reduce consumption. However, in sated mice 
given 2-h access to palatable chow, a 600-mg/kg dose was observed to effectively 
decrease intake. Thus, an effective anorexigenic dose of TRP depends on the 
nutritional and feeding motivational status stemming from hunger. 
Of note, in the previously mentioned scenarios, both the standard and palatable 
chow were calorie-dense, complex and stable diets, meaning they contain required 
macro- and micronutrients. Therefore, the question then arose as to whether TRP 
would reduce consumption of nutritionally inadequate non- and low-caloric 
solutions, whose intake is driven by palatability. Those experimental models are 
particularly important in identifying central mechanisms responsible for TRP-
induced hypophagia. Many neuroactive agents affect either only eating for energy 
(e.g., neuropeptide Y [34-39] and AGRP can motivate the consumption of calorie-
dense ingestants regardless of their palatability [40-43]) or eating for reward (e.g. 
opioids modify intake of energy-dilute palatable solutions [44-49]) or eating 
stimulated by both of these variables (e.g. OT decreases intake for both palatability 
and energy, by acting through disperse circuitry [30, 50]). 
TRP failed to reduce the consumption of all other solutions sweetened with sugar 
as well as with a non-carbohydrate, non-caloric sweetener, saccharin. Likewise, 




Therefore, in this context, regardless of whether the pleasant taste and/or 
postingestive effects are associated with fat or carbohydrate content or saccharin-
derived sweet flavour, TRP does not suppress palatability-driven intake. The 
absence of anorexigenic effects in these paradigms is striking when considering the 
fact that 1200 mg/kg TRP does reduce water consumption in thirsty mice, whereas 
the even higher 1800 mg/kg dose utilised in the sugar solution study had no effect. 
This emphasises the fact that the previously observed TRP-induced hypophagia, on 
palatable chow intake, is not associated with reward processing. Previous research 
demonstrated that intragastric TRP in rats was equally effective in reducing the 
intake of high-carbohydrate (and protein-free), as well as standard chow available 
in 12-h daily sessions [17]. Therefore, based on those findings and the data shown 
in this thesis, one can speculate that the mechanisms behind TRP’s anorexigenic 
effects are related to the hunger-satiation continuum rather than palatability-driven 
feeding. Notably, the effect of TRP on thirst may be a contributing factor to 
generalised hypophagia.  
The fact that intragastric administration of TRP does not always lead to inhibition 
of ingestive behaviour suggests that TRP-driven hypophagia is unrelated to 
sickness/malaise. The data obtained in our CTA experiment further underline this 
notion. Toxin-treated mice subjected to an aversion conditioning paradigm develop 
avoidance of a novel tastant when presented concurrently with a toxin [51-53].  The 
current data show that TRP-infused mice do not decrease preference towards the 
novel KoolAid solution in the CTA model. This instils greater confidence in 





The pattern of c-Fos immunoreactivity evoked by 1200 mg/kg TRP (the dose 
effective in all our feeding paradigms where intragastric TRP reduced consumption) 
was consistent with the earlier reports in rats, suggesting the significant role of 
brainstem circuitry in mediating amino acid-driven hypophagia [6]. Elevated NTS 
and DMNV neuronal activity indicates the importance of vagal afferents (for review, 
see [54]), whereas a minor (albeit, non-significant) increase in AP c-Fos levels 
suggests the involvement of this sensory circumventricular organ. c-Fos changes 
were observed outside of the brainstem, in other known feeding-related brain 
regions, which suggests that TRP engages more widespread networks (either in a 
direct or indirect manner). The most robust increase in neuronal activation was 
discovered in the hypothalamic PVN, DMH and SON. These three areas receive 
input from the brainstem [54] and characteristically show increased activity at meal 
termination, as well as with physiological changes that signify the need to cease 
consumption (e.g. stomach distension or elevated plasma osmolality) [55, 56]. This 
concurrent TRP-induced change in c-Fos immunoreactivity in the brainstem-
hypothalamic circuit is consistent with the proposed role for TRP in the regulation 
of feeding for energy, as suggested in an earlier study in rats [16, 17].  
Some aspects of the Fos pattern aligns well with the observed effect of TRP on 
thirst-driven water intake, as a subset of the activated sites mediates not just feeding, 
but also drinking behaviour [57]. For instance, the SON where vasopressin (VP) 
neurons are accumulated in its ventral portion, displays high c-Fos activation in the 
TRP group [58]; also the central nucleus of the amygdala (CeA), which, aside from 
mediating multiple anorexigenic signals, is involved in the regulation of osmotic 




AcbC and AcbS, regions usually associated with reward, showed a slight decline in 
c-Fos levels below control values. Therefore, this might indicate a connection 
between TRP and Acb-based mediating energy consumption, since meal size in 
energy-deprived rats is controlled via the accumbal circuitry too; as seen in the 
recent AcbC OT injection studies [30]. 
In sum, intragastric TRP reduces both food and water intake, and TRP-induced 
hypophagia appears to be potentially mediated via dispersed central circuits, most 
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3 Effects of intraperitoneal L-tryptophan on ingestive 
behaviour and neuronal activation in feeding-related 
brain sites 
3.1 Abstract 
In the previous chapter, I found that intragastric TRP moderately decreases feeding 
for energy. The analysis of c-Fos immunoreactivity after a hypophagic intragastric 
TRP dose showed increased activation of feeding-related hypothalamic and 
brainstem sites. In the current set of experiments, I investigated whether 
anorexigenic and brain activation effects persist when TRP administration bypasses 
the gut, i.e., TRP is injected directly in the intraperitoneal (IP) cavity in rats. The 
effect of IP TRP was examined in both energy- and palatability-induced feeding. 
30 and 100 mg/kg IP TRP suppressed chow intake in energy deprived rats. Only a 
higher 100 mg/kg IP TRP dose reduced consumption of palatable chow and 
palatable sucrose, saccharin and Intralipid solutions in sated animals. Thirst-driven 
water intake was reduced after both 30 and 100 mg/kg IP TRP. Neither 30 nor 100 
mg/kg IP TRP promoted the development of a conditioned taste aversion, which 
indicates a lack of treatment-induced sickness/malaise. The analysis of c-Fos in 
feeding-related brain sites showed the most pronounced effect of IP TRP on 
hypothalamic paraventricular and supraoptic nuclei and the nucleus of the solitary 
tract (NTS) in the brainstem. It can be concluded that IP TRP suppresses energy 




the same dose range, whereas higher doses are necessary to reduce consumption of 
palatable solutions in sated animals. IP TRP’s hypophagic effect is accompanied by 
enhanced activation of central circuitry that encompasses brainstem and 






Data presented in Chapter 2 characterising feeding effects of intragastric TRP 
strongly suggest that this essential amino acid generates moderate hypophagia.  
This outcome is in concert with the observations reported by Jordi and co-workers 
who found that gavaging animals with TRP prior to a standard meal produces a 
decrease in consumption that nears significance (only a trend was detected, though, 
as correction for multiple comparison was applied, because the effects of as many 
as 20 amino acids were analysed simultaneously) [1]. Similar to that study, our c-
Fos immunoreactivity mapping presented in Chapter 2 showed the involvement of 
the brainstem circuit, particularly the dorsal vagal complex (DVC). 
TRP levels have been found to rise in the general circulation within minutes after 
intragastric infusion [2]; TRP also crosses the BBB [3, 4]. Hence, it can be 
presumed that one way through which TRP exerts its anorexigenic action 
(especially, its portion likely mediated by the brain) is by directly interacting with 
CNS neurons. However, the few reports on the consequences of intragastric 
infusion of TRP published to date emphasise the concomitant release of select gut 
hormones (including glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK)) 
in response to the TRP treatment [5, 6]. It raises a question as to whether TRP-
driven anorexia observed after intragastric delivery may stem from the action of 
this amino acid on gut mucosa and submucosa. If so, this could be that the potential 
interaction with gut cells may be an underlying cause leading to changes in 
digestive functions, hormone release and/or GI motility, having all these factors 




brain activity after TRP. This is particularly pressing taking into account that 
hormones, such as CCK and GLP-1, decrease food intake, change gastric motility, 
stimulate c-Fos expression in the brainstem and affect activation of a wide brain 
circuitry encompassing, among others, the hypothalamus [7-10].  In order to 
address this dilemma, the current chapter is dedicated to studying feeding and brain 
activation effects of TRP delivered via a route that bypasses a direct contact with 
the gut mucosa, i.e., via an IP injection.  
Similar to the scarcity of data related to intragastric TRP, literature on feeding-
related effects of IP TRP is very limited. Early studies revealed a decrease in 
consumption in response to 75 mg/kg IP TRP in rats maintained on a choice of 10% 
or 60% casein diet, with a noticeable reduction in carbohydrate intake [11]. The IP 
TRP injection of 50 mg/kg and 100 mg/kg in 24 h-deprived rats reduced food intake 
by 20% and 30% respectively, after one hour of re-feeding [12, 13]. Furthermore, 
100 mg/kg TRP suppressed food intake by 33-45% in rats maintained on the 12-
h/day availability schedule of both standard and high-carbohydrate (protein-free) 
food. Interestingly, in that study noticeably higher plasma and brain TRP levels 
were observed after a 30-minute period when an equivalent TRP dose was 
administered IP rather than intragastrically [2]; this finding was further supported 
by [14]. On the other hand, Peters et al. failed to observe any effect of 100 mg/kg 
TRP on food intake in rats [15], although the cross-sectional design might have led 
to false negatives. Thus far, there have been no studies investigating effectiveness 




ore, the current set of studies was aimed to provide systematic characterisation of 
potential anorexigenic effects of IP TRP in the context of eating for energy, eating 
for palatability and drinking for thirst, as well as concurrent changes in brain 
activation.  
First, I examined the acute effects of IP TRP first on deprivation-induced intake of 
energy-dense standard chow, and then on the intake of energy-dense palatable chow 
in sated rats. A conditioned taste aversion (CTA) paradigm was utilised to exclude 
a possibility that TRP-driven anorexia arises from sickness/malaise [16]. Then, 
determined whether TRP is capable of diminishing palatability-driven consumption 
of calorie-dilute solutions; whose intake was unaffected in our previous intragastric 
TRP study (Chapter 2).  Furthermore, IP TRP’s effect on water intake in water-
deprived rats was analysed. Lastly, I expanded on the prior evidence indicating the 
involvement of the brain in mediating anorexigenic properties of TRP (Chapter 2). 
This was achieved by treating rats with a hypophagic dose of IP TRP and mapping 
c-Fos immunoreactivity in central sites known to control appetite, including the 
ones that were found to be affected by intragastric TRP as shown in the previous 
chapter.  
3.3 Materials and methods 
3.3.1 Animals and intraperitoneal administration 
Adult male Sprague–Dawley rats (AgResearch, Hamilton, NZ) weighing 250-260 
g at the beginning of the studies were housed individually in Plexiglas cages 




standard chow (Specialty Diets, Australia) unless specified otherwise. All 
procedures received prior approval from the University of Waikato animal ethics 
committee, and they are compliant with the NIH Guide for the Care and Use of 
Laboratory Animals (NIH Publ., no. 80–23, rev. 1996).  
Drugs and injections: TRP (Sigma, UK) were administered in isotonic saline. 
Animals were acclimatised to handling and receiving IP injections prior to the 
studies.  
3.3.2 Consummatory behaviour studies 
3.3.2.1 Effect of IP TRP on chow intake after overnight food deprivation 
 Overnight food-deprived rats were injected IP with 0 (saline), 10 mg/kg, 30 mg/kg 
or 100 mg/kg (n=7-11/group). The 100 mg/kg dose has been demonstrated to be 
effective in reducing food intake in rats [2]. Pre-weighed chow pellets were placed 
in food hoppers immediately after the treatment. Food intake was measured 1, 4 
and 24 h post-injection and corrected for spillage. 
3.3.2.2 Effect of IP TRP on deprivation-induced water intake  
Rats were water-deprived overnight and injected IP with either 0 (saline), 10, 30 or 
100 mg/kg TRP (n=10-14/group) prior to regaining access to water. At 10:00, water 
bottles were returned to the cages and intake was measured 1 h post-injection. Chow 




3.3.2.3 Effect of TRP on the intake of palatable chow in non-deprived rats 
In order to examine whether TRP decreases consumption of palatable solid food in 
non-deprived animals, following a previously published protocol ([9, 15]), and gave 
rats 2-h access to palatable goat milk-enriched chow (3.5 kcal/g; PFR, New Zealand) 
at 10:00. Five minutes earlier, the animals received IP TRP at 0 (saline), 30 or 100 
mg/kg (n=7-8/group). Standard chow was removed during the 2-h period of 
palatable diet availability. The animals had previous exposure to the palatable chow 
to avoid neophobia. 
3.3.2.4 Effect of TRP on the episodic intake of palatable solutions 
The paradigm described herein was based on the protocol used in our earlier studies 
[17-19]. Three cohorts of rats were accustomed to receiving 10% sucrose, 0.1% 
saccharin or 4.1% Intralipid palatable solutions for 1 h/day for 2 days (10:00-11:00) 
prior to the experiment to avoid neophobia (sucrose study: n=6-7/group; saccharin 
study: n=10/group; goat skim milk study: n=10/group; intralipid study: n=8-
9/group). On the experimental day, animals were given IP TRP (at 0 (saline), 30 
and 100 mg/kg TRP), 5 minutes before gaining access to the solutions. Chow and 
water were removed during the 2-h testing period. Palatable solution intake was 
measured after 1 h by weighing bottles.  
3.3.2.5 Effect of IP TRP on the acquisition of a conditioned taste aversion 
(CTA) 
In this standard CTA protocol (see e.g., [19]), rats had water taken away 16 h before 
their first exposure to a novel strawberry-flavoured KoolAid solution (1 h; 




instructions). Chow was removed at the time of fluid presentation. Afterwards they 
received an IP injection of 0 (saline), 30 or 100 mg/kg TRP (effective anorexigenic 
doses based on the aforementioned experiments; n=10/group). Rats treated with IP 
6 mEq LiCl (vs saline) served as a positive CTA control (n=7/group). One hour 
after the injections, water and chow were returned to the cages. Two days later, 
animals were deprived of water again for 16 h, however, on the subsequent day, 
they were given a two-bottle preference test between KoolAid and water for 2 h 
(chow removed during the test). Bottles were weighed and percentages of KoolAid 
intake (out of cumulative intake, i.e. KoolAid + water) were calculated to assess 
acquisition of a CTA to the flavoured solution. 
3.3.3 Immunohistochemistry 
The rats received either a single IP injection of 30 mg/kg TRP (this dose caused a 
decrease in deprivation-reduced chow intake) or vehicle (n=6/group). Immediately 
after the treatment, which was performed between 10:00-11:00, both food and water 
were removed from the cages. Animals were anaesthetised (35% urethane) and 
perfused with saline (50mL) followed by 500mL of 4% paraformaldehyde (PFA) 
in 0.1 M phosphate buffer (pH 7.4) between 80-90 minutes after TRP/vehicle 
infusions. Brains were removed and postfixed overnight in PFA at 4˚C. Coronal 60 
– um vibratome (Leica, Germany) sections were processed for c-Fos 
immunostaining. The tissue was treated for 10 minutes in 3% H2O2 in 10% 
methanol (in TBS; pH 7.4) and incubated overnight at 4˚C in the rabbit anti-Fos 
antibody (1:14000; Synaptic Systems, Goettingen, Germany). Subsequently, 
sections were incubated for 1 h in the goat-anti-rabbit antibody (1:400; Vector 




Laboratories). Peroxidase was visualised with 0.05% DAB, 0.01 % H2O2 and 0.2% 
nickel sulphate (Sigma, USA). All incubations were conducted in a mixture of 0.25% 
gelatin and 0.5% Triton X-100 (Sigma, USA) in TBS. Intermediate rinsing was 
performed with TBS. Sections were mounted on gelatinised slides, dried, 
dehydrated in ascending concentrations of ethanol, soaked in xylene and embedded 
in Entellan (Merck, Germany). The number of c-Fos immunoreactive nuclei was 
counted bilaterally in all regions of interest (4-5 sections containing a given site per 
animal). Densities of c-Fos positive nuclei (per mm2) were averaged per rat and 
then per group.  
3.3.4 Statistical analyses 
Data from all consummatory behaviour studies utilising single TRP administration 
were processed with a Student’s t-test (two-group comparisons) or a one-way 
ANOVA followed by Dunnet’s post-hoc analysis (multiple-group comparisons). 
Correction for multiple comparisons was applied. Immunohistochemistry were 
analysed with a Student’s t-test. Values are presented as means ± S.E.M and they 
were deemed significantly different when p≤0.05. 
3.4 Results 
IP TRP decreased deprivation-induced chow intake at 1 and 4 h post-injection 
(Figure 3.1A). At 1 h, 30 and 100 mg/kg were effective (F(3, 30)=24.9; p=0.001 
and p<0.001, respectively), whereas at 4 h, only animals treated with 100 mg/kg ate 




by 30 mg/kg and 100 mg/kg TRP (F(3, 41)=5.053; p=0.043 and p=0.042, 
respectively; Figure 3.1 B). 
In non-deprived animals given episodic access to either palatable solid or liquid 
tastants, 30 mg/kg TRP was ineffective (Figure 3.1 C/Figure 3.2 A-C). However, 
the 100-mg/kg dose decreased intake of palatable chow (F(2, 19)=3.46, p=0.031) 
(Figure 3.1 C), as well as of 10% sucrose (F(2, 17)=0.0278, p=0.0155) and 0.1% 
saccharin (F(2, 27)=4.389, p=0.0139) (Figure 3.2 D,E). The mean values for 
Intralipid intake after 100 mg/kg TRP were ca. 20% lower, but the difference did 
not reach significance. 
Neither 30 nor 100 mg/kg TRP supported the development of a CTA to a novel 
KoolAid solution, unlike the IP injection of LiCl (p<0.001), which caused a 60% 
decline in preference for this ingestant (Figure 3.3 A,B). 
The lowest anorexigenic dose of TRP (30 mg/kg) elevated c-Fos immunoreactivity 
in the NTS (p=0.006), PVN (p=0.0044) and SON (p=0.0015), and caused a 
significant decline in the density of c-Fos positive nuclei in the basolateral 
amygdala (BLA) (p=0.0223) (Figure 3.5 A-D). Also a decrease approaching 






Figure 3.1 Effect of IP TRP on standard chow intake induced by overnight energy 
deprivation (A), water intake induced by overnight water deprivation (B) and on 
consumption of palatable chow (C) in non-deprived animals. TRP doses shown in 
mg/kg (0 indicates saline control). */*** - significantly different from saline controls, 






 Figure 3.2 Effect of IP TRP on 10% sucrose (A), 0.1% saccharin (B) and 4.1% 
Intralipid (C) in non-deprived animals. TRP doses shown in mg/kg (0 indicates saline 







Figure 3.3 Effect of IP TRP on the acquisition of a CTA to a KoolAid solution (A). 
(B) shows a positive control for a CTA facilitated by an IP injection of LiCl. TRP 
doses shown in mg/kg (0 indicates saline control). */*** - significantly different from 







Figure 3.4 c-Fos immunoreactivity in select feeding-related brain sites following IP 
30 mg/kg TRP vs saline. The graph (A) shows densities of Fos positive nuclei per 
mm2 of each area of interest. AcbC – nucleus accumbens core; AcbS – nucleus 
accumbens shell; ARC – arcuate nucleus; BLA – basolateral amygdala; CeA – 
central nucleus of the amygdala; DMH – dorsomedial hypothalamic nucleus; DMNV 
– dorsal motor nucleus of the vagus; NTS – nucleus of the solitary tract; PVN – 
paraventricular hypothalamic nucleus; SON – supraoptic nucleus; STM – bed 
nucleus of the stria terminalis; VMH – ventromedial hypothalamic nucleus;  * - 







Figure 3.5  c-Fos immunoreactivity in select feeding-related brain sites following IP 
30 mg/kg TRP vs saline. Photomicrographs (A-D) depict c-Fos in brain areas in 
which a significant change was noted (control: left panels; TRP: right panel). 3v – 
third ventricle; BLA – basolateral amygdala; cc – central canal; NTS – nucleus of 
the solitary tract; otr – optic tract; PVN – paraventricular hypothalamic nucleus; 






As mentioned in the introductory chapter to this thesis, a high-protein content of a 
diet suppresses appetite [20-26]. The notion that some individual amino acids act 
as anorexigens [1, 2, 27-31] seems particularly attractive as it offers an avenue of 
practical approaches in which a reduction in appetite is achieved by – instead of 
complex and not too palatable protein – by some individual amino acid(s). As TRP 
has been proposed as a candidate molecule promoting hypophagia, it is critical to 
assess the range of its anorexigenic effects as well as mechanisms that it engages in 
order to reduce food intake. 
In Chapter 2 it was shown that intragastric TRP decreases deprivation-induced food 
intake and, at higher doses, thirst-induced drinking, but it is ineffective in changing 
consumption of palatable solutions. The data presented in this chapter indicate that 
IP TRP, thus TRP that does not come into contact with the gut mucosa, retains its 
anorexigenic properties. It should be noted, however, that the lowest dose of IP TRP 
that suppresses deprivation-induced chow intake is the same as the dose that 
decreases thirst-induced water drinking behaviour. This is in contrast to intragastric 
TRP, which induced effects on drinking at a dose that was 1/2log higher than that 
necessary to reduce hunger-driven intake of chow. Hence, while in the case of 
intragastric TRP, the effects on consummatory behaviour were more related to 
intake of calories, IP TRP appears to have a generalised suppressing effect on 
deprivation-induced intake of both food and water. Although it is a purely 
speculative statement, one can envision that the direct contact of TRP with gut 




originate in the GI tract (as mentioned earlier, GLP-1 and CCK belong to this 
category ([7-10])) that later become relayed either directly or via vagus to brain 
circuitry to produce changes in ingestive behaviour.    
IP TRP produced a very short-lasting hypophagia in energy-deprived rats. The 
reduction in chow intake was observed only in the first hour post-injection and it 
was compensated during the next 3 hours of re-feeding. It was therefore even a 
faster compensatory response than that noted after intragastric TRP, which 
maintained consumption at a lower level after 4 h (but not after 24 h) (Chapter 2).  
In the studies presented herein, 30 mg/kg was the lowest dose that decreased 
deprivation-induced intake of chow. It is only somewhat lower than the 50-100 
mg/kg range reported earlier for energy deprivation [12, 13] as well as for 12h-12h 
daily food access restriction [2]. Therefore, an anorexigenic IP TRP appears to have 
a greater effect on food intake related to energy status and hunger. 
While in animals having energy deficit, 30 mg/kg TRP was sufficient to decrease 
standard chow intake, in sated rats offered palatable chow, thus, motivated to eat 
by rewarding value of food, only the higher dose (100 mg/kg) reduced consumption. 
The same 100 mg/kg dose reduced intake of palatable solutions (sweet energy-
dilute sucrose and non-caloric saccharin, and Intralipid) in non-deprived rats, 
whereas 30 mg/kg remained ineffective, which underscores the relationship 
between TRP and deprivation. It is possible that composition of this liquid diet may 
have contributed to the heightened responsiveness to TRP, however, this should be 




Importantly, both 30 mg/kg and 100 mg/kg IP TRP reduced water intake in thirsty 
rats. Therefore, the same dose of IP TRP affected chow and water intake after 
deprivation. This is in contrast to the findings with intragastric TRP (Chapter 2) 
which had to be infused at a higher dose to reduce water than chow intake. This 
outcome calls into question whether the effect of IP TRP on consumption of 
palatable solutions in non-deprived animals is a direct consequence of TRP’s action 
on palatability-driven appetite or a secondary effect related to changes in drinking 
behaviour. The fact that 100 mg/kg IP TRP also diminished intake of palatable 
energy-dense chow in sated animals gives us greater confidence in that the observed 
effect on intake of rewarding tastants cannot be completely attributed to changes in 
thirst. Importantly, our CTA study utilising a standard protocol [19] demonstrated 
that peripheral administration of 30 mg/kg TRP (lowest anorexigenic dose) did not 
shift animals’ preference for a novel KoolAid solution, strongly indicating that this 
observed IP TRP-driven hypophagia is not related to sickness/malaise.  
The fact that distribution of c-Fos immunoreactivity induced by 30 mg/kg TRP was 
fairly consistent with the effect of intragastric TRP (Chapter 2), suggests that 
regardless of an administration route, TRP engages an overlapping set of sites. This 
was particularly apparent in relation to enhanced neuronal activation in the 
brainstem and hypothalamus. It underpins the importance of vagal input into the 
brainstem in mediating hypophagic properties of TRP, whereas c-Fos changes 
observed again in forebrain areas indicate the involvement of broader pathways 
interconnected with the brainstem (including those that encompass the 
hypothalamus, a key energy homeostasis controlling region) [32]. In previous 




termination of meal and, with physiological changes that signify the need to cease 
consumption (e.g. stomach distension or high plasma osmolality) [33, 34].  
It should be noted that some of those brain sites also influence drinking behaviour 
and again could offer insight into neural basis of the IP TRP-induced decline in 
water intake [35]. For example, the SON which showed increased c-Fos 
immunoreactivity in the IP TRP group, is involved in the regulation of osmotic 
balance and water intake via NTS-descending pathways and has a large number of 
VP neurons [36-39]. A slight c-Fos decrease was observed in the AcbS (not AcbC 
as with intragastric TRP), the area associated with reward. This provides further 
evidence for a possible link between TRP and accumbal-based regulation of 
consumption for energy: in food-deprived animals meal size is regulated via 
accumbal circuitry too, as observed in a recent AcbC OT injection studies [19]. 
Interestingly, an observed significant decrease in neuronal activation was detected 
in the BLA, one of the subdivisions of the AMY. The AMY is typically associated 
with the emotional aspects of feeding regulation and hunger-driven consummatory 
behaviour [40]. Additionally, it expresses a range of both hyperphagia and 
hypophagia mediating receptors, including those for opioids, OT and ghrelin [40-
42].  
Alterations in brainstem neuronal activity are consistent with earlier reports 
implicating brainstem circuitry with amino-acid driven hypophagia [1]. Analysis of 
c-Fos after hypophagic IP TRP dose demonstrated somewhat less pronounced 
neuronal activation than following intragastric TRP. Thereby, one can speculate 




tract hormones (e.g. GLP-1 or CCK) [23, 43-48] might make a difference in the 
ability of the brain to respond to the presence of TRP. This notion aligns well with 
Steinert et al. (2014) study who detected higher levels of CCK, glucagon and GLP-
1, alongside increased fullness, following the intraduodenal infusion of TRP [5]. 
In sum, it can be concluded that IP TRP suppresses energy deprivation-induced 
intake of standard chow and thirst-induced water intake. Higher doses are necessary 
to reduce consumption of palatable solutions; this hypophagic effect is facilitated 
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4 Tryptophan and Oxytocin 
4.1 Abstract 
Neural circuitry involved in mediating TRP-induced hypophagia has been poorly 
defined. The studies presented by other authors and in the earlier chapters of this 
thesis suggest the involvement of the brainstem-hypothalamic pathway. 
Interestingly, both intragastric and intraperitoneal (IP) TRP administered at 
hypophagic doses increase c-Fos immunoreactivity in the hypothalamic 
paraventricular (PVN) and supraoptic (SON) nuclei. These sites host neurons that 
synthesise a key satiety mediator, oxytocin (OT). Therefore, this chapter explored 
a hypothesis that TRP’s anorexigenic action relies on enhanced activity of the OT 
system. By employing double-immunohistochemistry, I determined that lowest 
effective doses of intragastric and IP TRP increased the percentage of Fos-positive 
OT neurons in the PVN and SON, although the effect was more pronounced after 
intragastric administration. Intragastric TRP also upregulated OT mRNA in the 
hypothalamus. A blood-brain barrier-penetrant OT receptor antagonist, L-368,899, 
reversed hypophagia induced by TRP administered via both routes. Unlike the 
lowest effective dose of intragastric TRP which decreases only feeding, IP TRP at 
the lowest effective dose diminishes both food and water intake. Hence it was 
confirmed that L-368,899 pre-treatment does not affect TRP-driven reduction in 
drinking behaviour. Overall, the findings strongly suggest a functional relationship 






The anorexigenic properties of the essential amino acid TRP have been well 
documented in an array of paradigms in earlier studies [1-4] as well as in the 
experiments shown in the previous sections of this thesis. Although evidence 
suggests that TRP-induced hypophagia is mediated via dispersed central circuitry 
(Chapter 2 & 3), the exact involvement of specific neural pathways and processes 
is unclear. This scarcity of precise information regarding the nature of central action 
of free amino acids is not unique to TRP. In fact, the only anorexigenic amino acid 
whose neural effects have been well  identified is leucine [5-8]: in rats, infusions of 
leucine into the third ventricle directly suppresses food intake via mTOR signalling 
and engages a network of hypothalamic sites that regulate appetite [5] (nota bene, 
peripheral hyperphagic rather than hypophagic action of leucine remains a largely 
unexplained phenomenon) [9-12]. 
Jordi and colleagues, who investigated the effect of isomolar intragastric doses of 
various individual amino acids, established that those that caused hypophagia (L-
arginine, L-lysine and L-glutamate) activate brainstem circuitry (most likely, 
through the AP and/or vagus-facilitated processing). In that report, however, a 
potential link between TRP and brainstem circuitry was not studied [1]. Sensory 
mechanisms at the CNS level for all other 19 amino acids (excluding leucine) and 
their involvement in food intake regulation have yet to be fully elucidated [1, 13]. 
Importantly, the results of the c-Fos experiments from both the intragastric and IP 
administration experiments, presented in Chapters 2 and 3 of this thesis, indicated 




doses of TRP. As the analysis of c-Fos throughout a host of feeding-related central 
sites revealed that the PVN and SON of the hypothalamus reliably show a 
significant increase in the number of c-Fos positive neurons, special attention was 
directed toward a key satiety mediator synthesised in these hypothalamic sites, 
oxytocin. I have postulated that a potential mechanism for TRP-driven hypophagia 
might involve circuitry that encompasses OT neurons. 
Oxytocin (OT) is a 9-amino acid neurohormone [14, 15] that inhibits feeding in 
order to protect internal milieu (e.g. energy balance, stomach distension and plasma 
osmolality) [16-20]. The increased activation of OT neurons and release of OT, 
correspond with the cessation of ingestive behaviour [21-26].  
Centrally acting OT stimulates suppression of food intake [24, 27, 28]. Arletti and 
colleagues, demonstrated that ICV OT infusions markedly reduced deprivation-
induced food intake in rats [24]. Since then, OT’s anorexigenic effect has been well 
established in relation to energy intake and, more recently, to palatability-driven 
consumption [23, 27, 29-31]. For example, OT-null knockout mice excessively 
consume palatable sweet solutions compared to wildtypes [32, 33]. The 
pharmacological blockade of the OT receptor by the BBB penetrant OT receptor 
antagonist, L-368,899, in sated mice prevents the anorexigenic effect of OT on the 
consumption of sweet tastants, and increases intake of such ingestants when the 
antagonist is administered alone [34]. 
OT appears to act as a cross-link for feeding termination between energy 
homeostasis and palatability-driven satiety, by acting through disperse central 




contains parvocellular cells that release OT centrally, by innervating diverse areas 
including the DVC [21, 40-46]. Other OT-expressing cells found in the PVN and 
the SON, belong to the magnocellular subpopulations which supply OT via 
somatodendritic projections into both periphery and the CNS [21, 40-43, 47-49]. 
The OT receptor has been found in high densities in regions associated with food 
reward (i.e. VTA and Acb), both of which are reciprocally interconnected with the 
PVN [50-53].  The intra-VTA and Acb infusions of OT dose-dependently decreased 
deprivation-induced chow intake and sucrose consumption in rats [35, 36]. 
Consequently, the current set of experiments focused on examining whether TRP-
driven anorexia is mediated via OT-encompassing circuitry. Double 
immunohistochemistry (c-Fos + OT) was employed following the lowest 
hypophagic doses of intraperitoneally and intragastrically administered TRP, to 
assess TRP-induced activation of OT neurons [54]. The effect of intragastric TRP 
on hypothalamic OT gene expression was assessed with real-time PCR (rtPCR). 
The functional importance of CNS circuits encompassing OT in mediating TRP-
driven hypophagia was further substantiated by showing the ability of OT receptor 
blockade, with an OT receptor antagonist L-368,899, to abolish intragastric and IP 




4.3 Material and methods 
4.3.1 Animals 
4.3.1.1 Intragastric Model 
Adult male C57BL/6 mice were housed individually under a 12:12 h light/dark 
cycle (lights on at 07:00) and maintained at a controlled temperature of 22˚C. The 
mice had ad libitum access to tap water and standard laboratory chow (Specialty 
Diets, Australia) unless specified otherwise. All procedures received prior approval 
from the University of Waikato animal ethics committee. 
4.3.1.2 Intraperitoneal Model 
Adult male Sprague–Dawley rats (AgResearch, Hamilton, NZ) weighing 250-260 
g at the beginning of the studies were housed individually in Plexiglas cages 
(LD 12:12, lights on at 07:00; 21°C). Rats had ad libitum access to water and 
standard chow (Specialty Diets, Australia) unless specified otherwise. All 
procedures received prior approval from the University of Waikato animal ethics 
committee, and they are compliant with the NIH Guide for the Care and Use of 
Laboratory Animals (NIH Publ., no. 80–23, rev. 1996). 
4.3.2 Drugs and injections  
4.3.2.1 Intragastric Model  
Mice were acclimatised to the oral gavage procedure prior to the studies. 




368,899 (Tocris, UK) were administered in isotonic saline. Mice were acclimatised 
to handling and receiving oral gavage and IP injections prior to the studies. 
4.3.2.2 Intraperitoneal Model  
TRP (Sigma, UK) and L-368,899 (Tocris, UK) were administered in isotonic saline. 
Rats were acclimatised to handling and receiving IP injections prior to the studies. 
4.3.3 Effect of OT receptor antagonist on the ability of intragastric TRP 
to reduce deprivation-induced intake of standard chow  
As TRP crosses the BBB, for the double-administration studies, the BBB-penetrant 
OT antagonist molecule, L-368,899 (Tocris) was selected [55]. IP administration 
of this ligand engages a combination of central and peripheral mechanisms, 
however at the dose range tested, it does not affect intake of standard chow [34]. 
Overnight food-deprived mice were double-treated with (a) IP saline- intragastric 
vehicle, (b) IP saline-intragastric TRP (1200 mg/kg), (c) IP L-368,899 (0.03 mg/kg) 
– intragastric TRP (1200 mg/kg), (d) IP L-368,899 (0.1 mg/kg) – intragastric TRP 
(1200 mg/kg), (e) IP L-368,899 (0.3 mg/kg) – intragastric TRP (1200 mg/kg) (n=8-
9/group). The two drug treatments were spaced 10-15 minutes apart from each other. 
Food was returned to cages 20 minutes after the second (i.e., TRP or vehicle) 
infusion and consumption was measured 1 h later. 
4.3.4 Effect of OT receptor blockade on the ability of IP TRP to reduce 
hunger-induced intake of chow  
 As TRP crosses the BBB, for the double-administration studies, the BBB-penetrant 




ligand engages a combination of central and peripheral mechanisms, however at the 
dose range tested, it does not affect intake of chow or water [10]. Rats were double-
treated IP with (a) saline + saline, (b) saline + TRP (30 mg/kg), (c) L-368,899 (1 
mg/kg) + TRP (30 mg/kg), (d) L-368,899 (1 mg/0kg) + saline (n=8/group). The two 
drug treatments were spaced 5 minutes apart from each other. Chow was returned 
to cages 5 minutes after the second (i.e., TRP/vehicle) injection (10:00-10:30) and 
consumption was measured 1 h later. 
4.3.5 Effect of OT receptor blockade on the ability of IP TRP to reduce 
thirst-induced intake of water   
Rats were water-deprived overnight and double-injected IP with (a) saline + saline, 
(b) saline + TRP (30 mg/kg), (c) L-368,899 (1 mg/kg) + saline, (d) L-368,899 (1 
mg/kg) + TRP (30 mg/kg) (n=8-9/group) (n=9-11/group) prior to regaining access 
to water. The injections were spaced 5 minutes apart from each other. Water bottles 
were returned to cages 5 minutes after the second (i.e., TRP or vehicle) 
injection (10:00-10:30), and intake was measured 1 h later. Chow was removed 
from hoppers during the drinking test. 
4.3.6 Effect of the lowest anorexigenic dose of intragastric TRP on 
activation of unidentified neurons in feeding-related brain sites 
and hypothalamic OT neurons 
The mice received either a single intragastric infusion of 1200 mg/kg TRP (the dose 
that decreased deprivation-induced chow intake) or water vehicle (n = 8/group for 




performed between 10:00-11:00, both food and water were removed from the cages. 
Animals were anaesthetised (35% urethane) and perfused with saline (20 mL) 
followed by 50 mL of 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 
7.4) between 80 and 90 min after TRP/vehicle infusions. Brains were removed and 
postfixed overnight in PFA at 4 ºC. Coronal 60-um vibratome (Leica, Germany) 
sections were processed for double-staining.  
For double immunohistochemistry (c-Fos + OT) with fluorescent staining, c-Fos 
visualisation was performed first using c-Fos primary antibody incubation and then 
later followed by OT labelling. First, the sections were treated for 10 min in 3% 
H2O2 in 10% methanol (in TBS; pH 7.4) and incubated overnight at 4ºC in the 
primary anti-rabbit Fos antibody (1:1400; Synaptic Systems, Goettingen, Germany). 
The following day, sections were rinsed and then incubated for 1 h in the secondary 
anti-rabbit antibody (DyLight 594 Goat Anti-Rabbit, 1:400, Vector Laboratories). 
These sections were then subject to OT labelling, the same protocol was followed 
except the 3% H2O2 in 10% methanol treatment was extended to 30 min. Also, a 1 
h blocking step with 1% bovine serum albumin (BSA) in TBS was added before 48 
h incubation with the primary OT (1:500; Millipore; anti-rabbit). After rinsing four 
times, sections were incubated for 24 h in the fluorescent secondary antibody 
(DyLight 488 Horse Anti-Rabbit, 1:500, Vector laboratories), before being rinsed 
again, mounted on gelatinised microscope slides, and after 2-3 min of drying, being 
embedded in DPX. All incubations were conducted in a mixture of 0.25% gelatin 





The sections were examined and photographed using a Nikon microscope equipped 
with an epifluorescent attachment, narrow-band filters and a camera. Co-
localisation of immunoreactivity for c-Fos and OT was ascertained by overlaying 
the captured images of each labelled product. The number of single and double-
labelled neurons was counted from these overlays. The percentage of c-Fos positive 
OT neurons in the paraventricular (PVN) and supraoptic (SON) nuclei was 
established per mouse and then per experimental group. 
4.3.7 Effect of the lowest anorexigenic dose of IP TRP on activation of 
unidentified neurons in feeding-related brain sites and 
hypothalamic OT neurons 
Neuronal activation (presence of an immediate-early gene product, c-Fos [56]) and 
biochemical phenotype of OT cells were determined with 
immunohistochemistry. The rats received an IP injection of 0 (saline) or 30 mg/kg 
TRP (the lowest hypophagic dose) or vehicle (n=6/group; injection time: 10:00-
11:00), and food and water were removed from the cages. Animals were 
anaesthetised (35% urethane) and perfused with saline (50mL) followed by 500mL 
of 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) 90 minutes after 
the treatment. Brains were removed and postfixed overnight in PFA at 4˚C. Coronal 
60–µm vibratome (Leica, Germany) sections were immunostained for c-Fos. The 
tissue was treated for 10 minutes with 3% H2O2 in 10% methanol (in TBS; pH 7.4) 
and incubated overnight at 4˚C in the rabbit anti-Fos antibody (1:14000; Synaptic 
Systems, Germany). Subsequently, sections were incubated for 1 h in the goat-anti-




Vector). Peroxidase was visualised with 0.05% DAB, 0.01% H2O2 and 0.2% nickel 
sulphate (Sigma, USA). Incubations were conducted in a mixture of 0.25% gelatin 
and 0.5% Triton X-100 (Sigma) in TBS. Intermediate rinsing was performed with 
TBS. Sections were mounted on gelatinised slides, dried, dehydrated in ethanol, 
soaked in xylene and embedded in Entellan (Merck, Germany). c-Fos IR nuclei 
were counted bilaterally (4-5 sections per site per animal), their densities (per mm2) 
were averaged per rat and then per group. 
In the c-Fos-OT double staining protocol, after completing the c-Fos detection 
process, hypothalamic sections underwent immunostaining again, however, this 
time, the primary OT antibody was used (1:8000; Millipore). No nickel sulphate 
was added to DAB, hence, OT immunoreactive cells displayed brown instead of 
black colour. The percentage of c-Fos positive OT neurons in the paraventricular 
(PVN) and supraoptic (SON) nuclei was established per rat and then per 
experimental group. 
4.3.8 Effect of intragastric TRP on relative expression of OT mRNA in 
the hypothalamus 
The mice received either a single intragastric infusion of 1200 mg/kg TRP 
(hypophagic dose) or water vehicle (n=8/group) at 10:00. Food and water were 
taken away right after the treatment and the mice were decapitated 3 hours later. 
Hypothalami were dissected and placed in RNAlater (Ambion). A standard protocol 
of sample preparation and rtPCR was followed and, for brevity, only the main steps 
are described here (see [5] for details). Samples were homogenised in TRIzol 




After centrifuging, the pellet was washed, dried, and dissolved in the DNase buffer 
(NEB). The samples were treated with RNase-free DNase I (Merck) and the 
absence of genomic DNA was established by PCR of a 5% template. 100ng/μl 
genomic DNA served as a positive control, whereas MilliQ H2O as a negative one. 
The product was analysed by electrophoresis. 5μg RNA samples were diluted with 
MilliQ H2O. RNA was reverse-transcribed in the master mix (Promega; 20μl). 
Samples were incubated for 1 h (37°C), followed by PCR to confirm cDNA 
synthesis. RtPCR reactions were performed in duplicates. Sample cDNA template 
(25ng) was used per primer [OT primer sequences: 
CGGTGGATCTCGGACTGAAC (fwd) and TAGCAGGCGGAGGTCAGAG 
(rev)]. Expression of four housekeeping genes (glyceraldehyde-3-phosphate- 
dehydrogenase, β-actin, β-tubulin, and ribosomal protein) was used to calculate 
normalisation factors (GeNorm). Primer efficiencies were calculated with 
LinRegPCR (HFRC) and Ct values were corrected for differences in primer 
efficiencies. 
4.3.9 Statistical analyses 
Data from all ingestive behaviour studies utilising a single injection were processed 
with a t-test (two-group comparisons) or a one-way ANOVA followed by Dunnet’s 
post-hoc analysis (multiple-group comparisons). Correction for multiple 
comparisons was applied. In the double-injection experiment, the t-test was used to 
establish the effect of IP TRP on deprivation-induced chow/water intake and then 
a one-way ANOVA followed by Dunnet’s test was applied to compare differences 




results were analysed with a t-test. Values are presented as means ± SEM and they 
were deemed significantly different for p≤0.05. 
4.4 Results 
4.4.1 Intragastric tryptophan preload 
In the hypothalamus, both the PVN and SON OT neurons were activated by TRP 
compared to vehicle (SON, P=0.004; PVN, P=0.001; Figure 4.2 A, B). Animals 
given TRP intragastrically showed an increase in hypothalamic OT mRNA levels 
(P=0.006; Figure 4.2 A). Pharmacological blockade of the OT receptors with the 
BBB-penetrant antagonist L-368,899 at 0.1 mg/kg (F(3, 29)=3.71; P=0.041) and 
0.3 mg/kg IP (P=0.048) attenuated TRP-induced hypophagia (P=0.001) in the post-






Figure 4.1 Intragastric TRP at 1200 mg/kg increases the percentage of c-Fos positive 
oxytocin (OT) neurons in the paraventricular (PVN) and supraoptic (SON) nuclei 
(A, B) Photomicrographs depict hypothalamic PVN sections stained for c-Fos (red) 







Figure 4.2 Intragastric TRP at 1200 mg/kg elevates relative expression of OT mRNA 
in the hypothalamus (A), whereas pretreatment with an intraperitoneal OT receptor 
antagonist, L-368,899, abolishes the anorexigenic effect of TRP in food-deprived 
mice during refeeding (B). Insert – Fos positive OT neuron; * - P≤0.05; ** - P≤0.01; 
*** - P≤0.001. 
4.4.2 Intraperitoneal tryptophan preload  
Double immunostaining revealed an increase in the percentage of activated OT 
neurons in the PVN (p<0.001) and SON (p=0.0427) in response to TRP (Figure 4.3 
A, B).  In feeding studies, only the effect of IP TRP on energy deprivation-induced 
chow intake (p=0.042) could be alleviated by antagonism of the OT receptor with 




intake (p<0.001) in thirsty rats remained the same after L-368,899 pretreatment 
(Figure 4.4 B).  
 
Figure 4.3 Activation (Fos IR) of OT neurons in the PVN and SON in response to 30 
mg/kg TRP vs saline control (A, B). Doses shown in mg/kg (0 indicates saline control). 
*/*** - significantly different from saline-injected controls, P≤0.05 and P≤0.001, 






Figure 4.4   The effect of 1 mg/kg OT antagonist, L-369,899, pretreatment on (A) 
TRP-induced reduction in chow intake after food deprivation, and (B) TRP-induced 
reduction in water intake after water deprivation. Doses shown in mg/kg (0 indicates 
saline control). */*** - significantly different from saline-injected controls, P≤0.05 







4.5 Discussion  
Central nervous system responses to fluctuations in nutrient levels are the most 
fundamental processes through which activity of neural and neuroendocrine 
pathways reflects (and responds to) the dynamic energy balance and to immediate 
changes in availability of key molecules obtained through ingestive behaviour. 
Most crucially, the presence of glucose sensing neurons in the brain has been well 
documented and their role in maintaining proper energy balance is unquestionable 
[57, 58]. It has been also shown that amino acids leucine, L-arginine, L-lysine and 
L-glutamate [1, 5-8, 59], affect the CNS, but the cellular events that ensue and 
broader pathways that are engaged by them have been precisely described only for 
leucine [1, 5-8, 13]. The data presented in this chapter strongly suggest that TRP 
requires the OT circuit to decrease energy intake, whereas in the case of TRP’s 
effect on water consumption, OT is non-obligatory.    
Food and water intake experiments reported in Chapters 2 and 3 of the current thesis 
indicate that intragastrically administered TRP suppresses energy intake at doses 
that are lower than those necessary to diminish thirst-driven drinking behaviour. On 
the other hand, IP TRP suppresses both drinking and eating within the same dose 
range. Previous injection studies utilising peripheral and central administration of 
OT have found that while the most consistent effect of OT is termination of food 
intake, also a decrease in water consumption can be observed [27, 29, 60]. Though 
the latter is not as frequently reported for all injection routes and pharmacological 
agents used [28, 35], it is nonetheless considered as a facet of pro-homeostatic 




might stem from control, for example, of osmolality and/or stomach distension [61-
63]. 
The fact that OT receptor blockade with an OT receptor antagonist, L-368,899, at 
a dose that does not affect consumption prevented TRP-driven decrease in chow 
intake strongly suggests that the involvement of the OT circuit is obligatory for 
satiating effect of TRP to occur. Importantly, this was evident in the case of both 
intragastric TRP and IP TRP, which indicates that regardless of whether TRP comes 
in contact with gastric mucosa or its administration mode bypasses the gut, its 
anorexigenic action relies on activation of OT neurons. L-368,899 being ineffective 
in alleviating TRP’s effect on deprivation-induced water intake suggests that while 
OT might still participate in this process, it is not essential for drinking behaviour 
reduction after IP TRP. Different pathways and neuronal populations facilitate 
feeding and drinking responses to TRP, but it is quite likely that to some extent they 
overlap (for example in the brainstem component – as evidenced in Chapters 2 and 
3 by similarity in c-Fos distribution after intragastric and IP TRP in the DVC, a 
region that receives vagal input and is partially devoid of the BBB [1, 64]). 
Considering that IP TRP-induced c-Fos immunoreactivity in the PVN and SON 
spreads beyond the identified OT neurons, it is quite possible that PVN and SON 
cells synthesising vasopressin (VP) are involved in the observed thirst effects. 
The release of the OT and enhanced OT neuronal activity coincide with satiation-
associated termination of feeding in laboratory animals [23-26]. Furthermore, a 
similar effect on OT system is stimulated by physiologically relevant peptidergic 




present set of data shows that the effect of both intragastric and IP TRP on OT 
neuronal activation parallels that induced by food loads as well as neuroactive 
agents that cause termination of consumption. That finding combined with the fact 
that TRP induces simultaneous activation of the key appetite-related brainstem 
circuit instils confidence in that TRP-derived hypophagia is indeed of physiological 
relevance and that the pathways involved in that process encompass OT. 
One should note that the OT neuronal activation in animals infused with intragastric 
TRP was higher than in IP TRP-treated individuals. On the one hand, it may reflect 
the direct effect of TRP on gastric mucosa and, consequently, a hypothetical link it 
with, e.g., a release of select gut hormones, such as GLP-1 or CCK [69-72]. It is 
indeed quite possible taking into account the results of a 2014 study in humans 
showing that intraduodenal TRP increased levels of CCK, glucagon, and GLP-1, 
leading to increased fullness and substantially decreased energy intake 
[4]. However, it is also conceivable that gut stimulation by insertion of the 
intragastric probe added to the magnitude of the OT response (purely, as a 
consequence of mechanical stimulation of the GI tract): that vehicle-infused 
animals have a higher baseline activity than IP controls would support this notion. 
Nonetheless, the overall increase in both OT neuronal activity (in Fos studies) and 
OT mRNA expression after TRP signifies a functional relationship between the 
presence of this amino acid and responsiveness of the OT system. 
It should also be mentioned that, although not formally determined due to the 
limited number of animals per group, TRP affected both magno- and parvocellular 




whereas the SON hosts magnocellular OT cells [31]. Parvocellular OT neurons 
release OT centrally, innervating numerous central areas, including the DVC [21, 
40-46]. Other OT magnocellular subpopulations release OT via somatodendritic 
projections into the periphery (via neurohypophysis) and at central targets [21, 40-
43, 47-49]. That TRP seems to affect both elements of the OT circuit, it can be 
speculated that it might thereby affect CNS-driven processes (via the DVC input) 
as well as peripheral mechanisms (through circulating OT). 
What remains to be elucidated is why TRP (regardless of its route of administration) 
is such a weak inhibitor of eating for palatability, especially when caloric density is 
low. It is particularly surprising considering that the OT receptor is highly expressed 
in brain regions associated with food reward, with PVN OT neurons innervating 
these key regions [50, 51]. These regions include the VTA, Acb, and BNST [50, 51, 
73]. OT receptor blockade by the BBB-penetrant antagonist, L-368,899, prolongs 
intake of palatable sweet solutions. Mullis and colleagues demonstrated that direct 
VTA OT administration reduced reward-driven sucrose consumption which was 
reversible with a pre-treatment with L-368,899 [36]. Intra-Acb and intra-amygdalar 
infusions of OT have been shown to promote sugar water consumption [35, 74]. 
Hence, the fact that TRP does not potently affect the portion of feeding driven by 
pleasure, it can be presumed that only a subset of hypophagia promoting OT 
neurons is engaged by TRP. 
In sum, the findings outlined in this chapter strongly suggest that OT is an important 











1. Jordi, J., B. Herzog, S.M. Camargo, C.N. Boyle, T.A. Lutz, and F. Verrey, 
Specific amino acids inhibit food intake via the area postrema or vagal 
afferents. J Physiol, 2013. 591(22): p. 5611-21. 
2. Ng, L.T. and G.H. Anderson, Route of administration of tryptophan and 
tyrosine affects short-term food intake and plasma and brain amino acid 
concentrations in rats. J Nutr, 1992. 122(2): p. 283-93. 
3. Ayaso, R., H. Ghattas, M. Abiad, and O. Obeid, Meal pattern of male rats 
maintained on amino acid supplemented diets: the effect of tryptophan, 
lysine, arginine, proline and threonine. Nutrients, 2014. 6(7): p. 2509-22. 
4. Steinert, R.E., N.D. Luscombe-Marsh, T.J. Little, S. Standfield, B. Otto, M. 
Horowitz, and C. Feinle-Bisset, Effects of intraduodenal infusion of L-
tryptophan on ad libitum eating, antropyloroduodenal motility, glycemia, 
insulinemia, and gut peptide secretion in healthy men. J Clin Endocrinol 
Metab, 2014. 99(9): p. 3275-84. 
5. Cota, D., K. Proulx, K.A. Smith, S.C. Kozma, G. Thomas, S.C. Woods, and 
R.J. Seeley, Hypothalamic mTOR signaling regulates food intake. Science, 
2006. 312(5775): p. 927-30. 
6. Morrison, C.D., X. Xi, C.L. White, J. Ye, and R.J. Martin, Amino acids 
inhibit Agrp gene expression via an mTOR-dependent mechanism. Am J 
Physiol Endocrinol Metab, 2007. 293(1): p. E165-71. 
7. Blouet, C. and G.J. Schwartz, Brainstem nutrient sensing in the nucleus of 
the solitary tract inhibits feeding. Cell Metab, 2012. 16(5): p. 579-87. 
8. Blouet, C., Y.H. Jo, X. Li, and G.J. Schwartz, Mediobasal hypothalamic 
leucine sensing regulates food intake through activation of a hypothalamus-
brainstem circuit. J Neurosci, 2009. 29(26): p. 8302-11. 
9. Morrison, C.D., S.D. Reed, and T.M. Henagan, Homeostatic regulation of 
protein intake: in search of a mechanism. Am J Physiol Regul Integr Comp 
Physiol, 2012. 302(8): p. R917-28. 
10. Laviano, A., M.M. Meguid, A. Inui, and F. Rossi-Fanelli, Role of leucine in 





11. Wang, S.B., P. Khondowe, S.F. Chen, J.J. Yu, G. Shu, X.T. Zhu, L.N. Wang, 
P. Gao, Q.Y. Xi, Y.L. Zhang, and Q.Y. Jiang, Effects of "Bioactive" amino 
acids leucine, glutamate, arginine and tryptophan on feed intake and mRNA 
expression of relative neuropeptides in broiler chicks. Journal of Animal 
Science and Biotechnology, 2012. 3. 
12. Purpera, M.N., L. Shen, M. Taghavi, H. Munzberg, R.J. Martin, S.M. 
Hutson, and C.D. Morrison, Impaired branched chain amino acid 
metabolism alters feeding behavior and increases orexigenic neuropeptide 
expression in the hypothalamus. J Endocrinol, 2012. 212(1): p. 85-94. 
13. McGavigan, A.K., H.C. O'Hara, A. Amin, J. Kinsey-Jones, E. Spreckley, A. 
Alamshah, A. Agahi, K. Banks, R. France, G. Hyberg, C. Wong, G.A. 
Bewick, J.V. Gardiner, A. Lehmann, N.M. Martin, M.A. Ghatei, S.R. 
Bloom, and K.G. Murphy, L-cysteine suppresses ghrelin and reduces 
appetite in rodents and humans. Int J Obes (Lond), 2015. 39(3): p. 447-55. 
14. Moos, F. and P. Richard, Paraventricular and supraoptic bursting oxytocin 
cells in rat are locally regulated by oxytocin and functionally related. J 
Physiol, 1989. 408: p. 1-18. 
15. Olszewski, P.K., A. Klockars, H.B. Schioth, and A.S. Levine, Oxytocin as 
feeding inhibitor: maintaining homeostasis in consummatory behavior. 
Pharmacol Biochem Behav, 2010. 97(1): p. 47-54. 
16. Swanson, L.W. and P.E. Sawchenko, Hypothalamic integration: 
organization of the paraventricular and supraoptic nuclei. Annu Rev 
Neurosci, 1983. 6: p. 269-324. 
17. Johnstone, L.E., T.M. Fong, and G. Leng, Neuronal activation in the 
hypothalamus and brainstem during feeding in rats. Cell Metab, 2006. 4(4): 
p. 313-21. 
18. Yamashita, M., Y. Takayanagi, M. Yoshida, K. Nishimori, M. Kusama, and 
T. Onaka, Involvement of prolactin-releasing peptide in the activation of 
oxytocin neurones in response to food intake. J Neuroendocrinol, 2013. 




19. Lokrantz, C.M., K. Uvnas-Moberg, and J.M. Kaplan, Effects of central 
oxytocin administration on intraoral intake of glucose in deprived and 
nondeprived rats. Physiol Behav, 1997. 62(2): p. 347-52. 
20. Olszewski, P.K., A. Klockars, A.M. Olszewska, R. Fredriksson, H.B. 
Schioth, and A.S. Levine, Molecular, immunohistochemical, and 
pharmacological evidence of oxytocin's role as inhibitor of carbohydrate 
but not fat intake. Endocrinology, 2010. 151(10): p. 4736-44. 
21. Huang, W., A.F. Sved, and E.M. Stricker, Vasopressin and oxytocin release 
evoked by NaCl loads are selectively blunted by area postrema lesions. Am 
J Physiol Regul Integr Comp Physiol, 2000. 278(3): p. R732-40. 
22. McCann, M.J. and R.C. Rogers, Oxytocin excites gastric-related neurones 
in rat dorsal vagal complex. J Physiol, 1990. 428: p. 95-108. 
23. Olson, B.R., M.D. Drutarosky, M.S. Chow, V.J. Hruby, E.M. Stricker, and 
J.G. Verbalis, Oxytocin and an oxytocin agonist administered centrally 
decrease food intake in rats. Peptides, 1991. 12(1): p. 113-8. 
24. Arletti, R., A. Benelli, and A. Bertolini, Influence of oxytocin on feeding 
behavior in the rat. Peptides, 1989. 10(1): p. 89-93. 
25. Deblon, N., C. Veyrat-Durebex, L. Bourgoin, A. Caillon, A.L. Bussier, S. 
Petrosino, F. Piscitelli, J.J. Legros, V. Geenen, M. Foti, W. Wahli, V. Di 
Marzo, and F. Rohner-Jeanrenaud, Mechanisms of the anti-obesity effects of 
oxytocin in diet-induced obese rats. PLoS One, 2011. 6(9): p. e25565. 
26. Sabatier, N., G. Leng, and J. Menzies, Oxytocin, feeding, and satiety. Front 
Endocrinol (Lausanne), 2013. 4: p. 35. 
27. Arletti, R., A. Benelli, and A. Bertolini, Oxytocin inhibits food and fluid 
intake in rats. Physiol Behav, 1990. 48(6): p. 825-30. 
28. Ho, J.M., V.T. Anekonda, B.W. Thompson, M. Zhu, R.W. Curry, B.H. 
Hwang, G.J. Morton, M.W. Schwartz, D.G. Baskin, S.M. Appleyard, and 
J.E. Blevins, Hindbrain Oxytocin Receptors Contribute to the Effects of 
Circulating Oxytocin on Food Intake in Male Rats. Endocrinology, 2014. 




29. Benelli, A., A. Bertolini, and R. Arletti, Oxytocin-induced inhibition of 
feeding and drinking: no sexual dimorphism in rats. Neuropeptides, 1991. 
20(1): p. 57-62. 
30. Klockars, A., C. Brunton, L. Li, A.S. Levine, and P.K. Olszewski, 
Intravenous administration of oxytocin in rats acutely decreases 
deprivation-induced chow intake, but it fails to affect consumption of 
palatable solutions. Peptides, 2017. 93: p. 13-19. 
31. Klockars, A., A.S. Levine, and P.K. Olszewski, Central oxytocin and food 
intake: focus on macronutrient-driven reward. Front Endocrinol (Lausanne), 
2015. 6: p. 65. 
32. Amico, J.A., R.R. Vollmer, H.M. Cai, J.A. Miedlar, and L. Rinaman, 
Enhanced initial and sustained intake of sucrose solution in mice with an 
oxytocin gene deletion. Am J Physiol Regul Integr Comp Physiol, 2005. 
289(6): p. R1798-806. 
33. Billings, L.B., J.A. Spero, R.R. Vollmer, and J.A. Amico, Oxytocin null 
mice ingest enhanced amounts of sweet solutions during light and dark 
cycles and during repeated shaker stress. Behav Brain Res, 2006. 171(1): 
p. 134-41. 
34. Herisson, F.M., L.L. Brooks, J.R. Waas, A.S. Levine, and P.K. Olszewski, 
Functional relationship between oxytocin and appetite for carbohydrates 
versus saccharin. Neuroreport, 2014. 25(12): p. 909-14. 
35. Herisson, F.M., J.R. Waas, R. Fredriksson, H.B. Schioth, A.S. Levine, and 
P.K. Olszewski, Oxytocin Acting in the Nucleus Accumbens Core Decreases 
Food Intake. J Neuroendocrinol, 2016. 28(4). 
36. Mullis, K., K. Kay, and D.L. Williams, Oxytocin action in the ventral 
tegmental area affects sucrose intake. Brain Res, 2013. 1513: p. 85-91. 
37. Leibowitz, S.F., N.J. Hammer, and K. Chang, Hypothalamic 
paraventricular nucleus lesions produce overeating and obesity in the rat. 
Physiol Behav, 1981. 27(6): p. 1031-40. 
38. Sims, J.S. and J.F. Lorden, Effect of paraventricular nucleus lesions on body 





39. Shor-Posner, G., A.P. Azar, S. Insinga, and S.F. Leibowitz, Deficits in the 
control of food intake after hypothalamic paraventricular nucleus lesions. 
Physiol Behav, 1985. 35(6): p. 883-90. 
40. Sagar, S.M., K.J. Price, N.W. Kasting, and F.R. Sharp, Anatomic patterns 
of Fos immunostaining in rat brain following systemic endotoxin 
administration. Brain Res Bull, 1995. 36(4): p. 381-92. 
41. Siaud, P., R. Puech, I. Assenmacher, and G. Alonso, Microinjection of 
oxytocin into the dorsal vagal complex decreases pancreatic insulin 
secretion. Brain Res, 1991. 546(2): p. 190-4. 
42. Hornby, P.J., Central neurocircuitry associated with emesis. Am J Med, 
2001. 111 Suppl 8A: p. 106S-112S. 
43. Charpak, S., W.E. Armstrong, M. Muhlethaler, and J.J. Dreifuss, 
Stimulatory action of oxytocin on neurones of the dorsal motor nucleus of 
the vagus nerve. Brain Res, 1984. 300(1): p. 83-9. 
44. Kirchgessner, A.L. and A. Sclafani, PVN-hindbrain pathway involved in the 
hypothalamic hyperphagia-obesity syndrome. Physiol Behav, 1988. 42(6): 
p. 517-28. 
45. Blevins, J.E., M.W. Schwartz, and D.G. Baskin, Evidence that 
paraventricular nucleus oxytocin neurons link hypothalamic leptin action 
to caudal brain stem nuclei controlling meal size. Am J Physiol Regul Integr 
Comp Physiol, 2004. 287(1): p. R87-96. 
46. Geerling, J.C., J.W. Shin, P.C. Chimenti, and A.D. Loewy, Paraventricular 
hypothalamic nucleus: axonal projections to the brainstem. J Comp Neurol, 
2010. 518(9): p. 1460-99. 
47. Pow, D.V. and J.F. Morris, Dendrites of hypothalamic magnocellular 
neurons release neurohypophysial peptides by exocytosis. Neuroscience, 
1989. 32(2): p. 435-9. 
48. Miyagawa, A., H. Okamura, and Y. Ibata, Coexistence of oxytocin and 
NADPH-diaphorase in magnocellular neurons of the paraventricular and 
the supraoptic nuclei of the rat hypothalamus. Neurosci Lett, 1994. 171(1-




49. de Kock, C.P., K.D. Wierda, L.W. Bosman, R. Min, J.J. Koksma, H.D. 
Mansvelder, M. Verhage, and A.B. Brussaard, Somatodendritic secretion in 
oxytocin neurons is upregulated during the female reproductive cycle. J 
Neurosci, 2003. 23(7): p. 2726-34. 
50. Qi, J., J.Y. Yang, M. Song, Y. Li, F. Wang, and C.F. Wu, Inhibition by 
oxytocin of methamphetamine-induced hyperactivity related to dopamine 
turnover in the mesolimbic region in mice. Naunyn Schmiedebergs Arch 
Pharmacol, 2008. 376(6): p. 441-8. 
51. Gould, B.R. and H.H. Zingg, Mapping oxytocin receptor gene expression 
in the mouse brain and mammary gland using an oxytocin receptor-LacZ 
reporter mouse. Neuroscience, 2003. 122(1): p. 155-67. 
52. Sofroniew, M.V., Projections from vasopressin, oxytocin, and neurophysin 
neurons to neural targets in the rat and human. J Histochem Cytochem, 
1980. 28(5): p. 475-8. 
53. Succu, S., F. Sanna, C. Cocco, T. Melis, A. Boi, G.L. Ferri, A. Argiolas, and 
M.R. Melis, Oxytocin induces penile erection when injected into the ventral 
tegmental area of male rats: role of nitric oxide and cyclic GMP. Eur J 
Neurosci, 2008. 28(4): p. 813-21. 
54. Olszewski, P.K., A. Klockars, and A.S. Levine, Oxytocin: A Conditional 
Anorexigen whose Effects on Appetite Depend on the Physiological, 
Behavioural and Social Contexts. J Neuroendocrinol, 2016. 28(4). 
55. Boccia, M.L., A.P. Goursaud, J. Bachevalier, K.D. Anderson, and C.A. 
Pedersen, Peripherally administered non-peptide oxytocin antagonist, 
L368,899, accumulates in limbic brain areas: a new pharmacological tool 
for the study of social motivation in non-human primates. Horm Behav, 
2007. 52(3): p. 344-51. 
56. Kovacs, K.J., Measurement of immediate-early gene activation- c-fos and 
beyond. J Neuroendocrinol, 2008. 20(6): p. 665-72. 
57. Routh, V.H., L. Hao, A.M. Santiago, Z. Sheng, and C. Zhou, Hypothalamic 




58. Steinbusch, L., G. Labouebe, and B. Thorens, Brain glucose sensing in 
homeostatic and hedonic regulation. Trends Endocrinol Metab, 2015. 26(9): 
p. 455-66. 
59. Alamshah, A., A.K. McGavigan, E. Spreckley, J.S. Kinsey-Jones, A. Amin, 
I.R. Tough, H.C. O'Hara, A. Moolla, K. Banks, R. France, G. Hyberg, M. 
Norton, W. Cheong, A. Lehmann, S.R. Bloom, H.M. Cox, and K.G. Murphy, 
L-arginine promotes gut hormone release and reduces food intake in 
rodents. Diabetes Obes Metab, 2016. 18(5): p. 508-18. 
60. Bernal, A., J. Mahia, and A. Puerto, Oxytocin, water intake, and food 
sodium availability in male rats. Horm Behav, 2007. 52(3): p. 289-96. 
61. Calatayud, S., E. Quintana, J. Esplugues, and M.D. Barrachina, Role of 
central oxytocin in the inhibition by endotoxin of distension-stimulated 
gastric acid secretion. Naunyn Schmiedebergs Arch Pharmacol, 1999. 
360(6): p. 676-82. 
62. Renaud, L.P., M. Tang, M.J. McCann, E.M. Stricker, and J.G. Verbalis, 
Cholecystokinin and gastric distension activate oxytocinergic cells in rat 
hypothalamus. Am J Physiol, 1987. 253(4 Pt 2): p. R661-5. 
63. Nelson, E.E., J.R. Alberts, Y. Tian, and J.G. Verbalis, Oxytocin is elevated 
in plasma of 10-day-old rats following gastric distension. Brain Res Dev 
Brain Res, 1998. 111(2): p. 301-3. 
64. Zuger, D., K. Forster, T.A. Lutz, and T. Riediger, Amylin and GLP-1 target 
different populations of area postrema neurons that are both modulated by 
nutrient stimuli. Physiol Behav, 2013. 112-113: p. 61-9. 
65. Bojanowska, E. and B. Stempniak, tGLP-1 and release of vasopressin and 
oxytocin from the isolated rat hypothalamo-neurohypophysial system: 
effects of a tGLP-1 receptor agonist and antagonist. J Physiol Pharmacol, 
2001. 52(4 Pt 2): p. 781-93. 
66. Ladyman, S.R., R.A. Augustine, E. Scherf, H.R. Phillipps, C.H. Brown, and 
D.R. Grattan, Attenuated hypothalamic responses to alpha-melanocyte 





67. Ohlsson, B., M.L. Forsling, J.F. Rehfeld, and K. Sjolund, Cholecystokinin 
stimulation leads to increased oxytocin secretion in women. Eur J Surg, 
2002. 168(2): p. 114-8. 
68. Verbalis, J.G., M.J. McCann, C.M. McHale, and E.M. Stricker, Oxytocin 
secretion in response to cholecystokinin and food: differentiation of nausea 
from satiety. Science, 1986. 232(4756): p. 1417-9. 
69. Ritter, R.C., Gastrointestinal mechanisms of satiation for food. Physiol 
Behav, 2004. 81(2): p. 249-73. 
70. Morton, G.J., D.E. Cummings, D.G. Baskin, G.S. Barsh, and M.W. 
Schwartz, Central nervous system control of food intake and body weight. 
Nature, 2006. 443(7109): p. 289-95. 
71. Cummings, D.E. and J. Overduin, Gastrointestinal regulation of food intake. 
J Clin Invest, 2007. 117(1): p. 13-23. 
72. Guyenet, S.J. and M.W. Schwartz, Clinical review: Regulation of food 
intake, energy balance, and body fat mass: implications for the 
pathogenesis and treatment of obesity. J Clin Endocrinol Metab, 2012. 97(3): 
p. 745-55. 
73. Jarrett, T.M., M.S. McMurray, C.H. Walker, and J.M. Johns, Cocaine 
treatment alters oxytocin receptor binding but not mRNA production in 
postpartum rat dams. Neuropeptides, 2006. 40(3): p. 161-7. 
74. Klockars, O.A., A. Klockars, A.S. Levine, and P.K. Olszewski, Oxytocin 
administration in the basolateral and central nuclei of amygdala 





5 Discussion and Perspectives 
Obesity arises from a dysregulation in energy balance when an individual’s energy 
intake habitually exceeds total energy expenditure [1-4]. Human and laboratory 
animal studies have consistently demonstrated that individuals eat not only to 
satisfy energy needs, but also (and, in the obesogenic environment, primarily) for 
reward [5]. Palatability to a great extent drives this overconsumption of energy by 
stimulating appetite despite the lack of underlying energy deficit and, importantly, 
by delaying satiety regardless of the fact that a large amount of energy has been 
ingested [6, 7]. When these phenomena occur sporadically, i.e., under relative 
scarcity of palatable food, they prove beneficial for an individual in that they propel 
search for and avid consumption of diets that are caloric and tasty. However, 
unrestricted and constant access to palatable foods continues to engage these 
mechanisms, even though these processes become redundant (and, eventually, 
harmful, when they lead to obesity) in the evolutionarily unique ‘environment of 
plenty’. Dysregulation of energy homeostasis ensues, at it is accompanied by 
elements of addictive-like overeating, aberrant peripheral hormonal release and 
delayed satiety signalling within relevant brain circuits ([8] – to review). Hence, an 
ongoing quest for developing strategies to overcome excessive food consumption 
is aimed at identifying molecules and processes that can alleviate the severity of or 
reverse appetite dysregulation.  
One of the fundamental strategies involves manipulating composition of a diet so 
that it becomes ‘satiating’ (a broad and colloquial term that encompasses diverse 




high-protein diets have generated interest for decades as a phenomenon of protein-
derived satiety has been well documented in numerous studies [9-15]. The anorectic 
effect of protein has been linked to oral, postoral and postabsorptive mechanisms, 
including changes in consumption-related reward, satiation, and energy metabolism 
[9-11]. However, it was well understood that protein is digested to individual amino 
acids, thus, at least a portion of the appetite regulatory role of protein could be 
attributed to them [16]; it is especially likely in relation to essential amino acids, 
which are not synthesised by the mammalian organisms [17]. This has a significant 
potential from the therapeutic standpoint as select individual amino acids – should 
they be used in obesity treatments – might have a better palatability/acceptability 
profile and their minimum concentrations/frequency of dosing might be easier to 
determine and control. 
Before undertaking the experimental work required for this thesis, it was evident 
that some amino acids exhibit anorexigenic effects. For example, it has been shown 
that leucine, L-arginine, L-lysine and L-glutamate [18-21], decrease food intake by 
utilising CNS mechanisms, but the precise cellular events and broader pathways 
engaged by them are defined in detail only for leucine [18, 20-24]. Limited studies 
focused on the essential amino acid, TRP. Some suggested that peripherally 
administered TRP (via injection or oral/gastric delivery) produces hypophagia, 
whereas others reported no effect [18, 25-30]. However, considering the ability of 
ingested TRP to enter not only the general circulation, but also readily cross the 
BBB, it seemed apparent that role of this key player in neurotransmitter and 





The current set of studies shows that free TRP administered before a meal is indeed 
an anorexigen. It decreases intake of energy by engaging broad feeding-related 
brain circuitry, including pathways that encompass OT, and it does so without 
producing undesirable malaise. At the same time, TRP does not seem to be similarly 
effective in decreasing a drive for palatable solutions, which is critical considering 
a strong link between palatability and excessive consumption. 
Our investigations confirmed effectiveness of TRP, regardless whether intragastric 
or IP, to reduce the intake of energy-dense diets, especially in response to energy 
deficit. The intragastric infusion of 600 mg/kg TRP in overnight deprived mice 
reduced the intake of standard chow, this was in line with the proposed role of 
dietary amino acids in promoting early satiation thereby decreasing meal size [25]. 
30 mg/kg IP TRP, a dose only somewhat lower than in earlier reports [26, 29], 
reduced the intake of standard chow in hungry rats. In sated mice motivated to eat 
by palatability, intragastric TRP was necessary to decrease episodic consumption 
of energy-dense palatable chow, although a higher 1200 mg/kg was needed to 
produce this effect in the absence of hunger (compared to 600-mg/kg dose in 
deprivation-induced feeding). In line with that, in sated rats, only the higher dose 
of 100 mg/kg IP TRP managed to reduce consumption of palatable chow. Thus, it 
appears that an effective dose of TRP needed to produce food intake termination 
depends on energy needs. 
Importantly, in the aforementioned experiments, both the standard and palatable 
chow were the calorie-dense, complex and balanced diets containing the essential 




also diminish intake of nutritionally inadequate non- and low-calorie solutions in 
paradigms in which consumption is driven entirely by palatability. This is 
particularly important for understanding central mechanisms that underlie TRP-
driven hypophagia as many neuroactive mediators affect either eating for energy 
(e.g., NPY [31-36] and AGRP [37-40]) or eating for reward (e.g. opioid receptor 
ligands preferentially modify intake of energy-dilute palatable sweet and fatty 
solutions regardless of energy needs [41-46]) or eating stimulated by both of these 
variables (e.g. OT decreases intake for both palatability and energy, by acting 
through disperse circuitry [47, 48]. Intragastric TRP even at doses up to 1800 mg/kg, 
failed to decrease intake of non- and low- caloric solutions including an Intralipid 
emulsion, sucrose and saccharin solutions. In sated rats motivated to eat by 
palatability, TRP needed to be administered at a higher, 100-mg/kg dose, to reduce 
consumption of palatable solutions. Therefore, it seems that in both intragastric and 
IP TRP delivery routes, palatability-driven feeding mechanisms are not the key 
regulatory processes affected by this amino acid.  
The lack of effect on the intake of the palatable solutions is particularly striking 
when considering the fact that 1200 mg/kg intragastric TRP suppressed water intake 
in thirsty mice (in contrast, even the 1800 mg/kg dose employed in the sucrose 
solution study had no effect). Similarly, IP TRP (both 30 mg/kg and 100 mg/kg) 
reduced water intake in thirst-driven rats. The analysis of water intake via the 
intragastric route indicated the suppression of energy intake at doses that are lower 
than those necessary to diminish thirst-driven behaviour. However, after IP TRP 
infusion both drinking, and eating were supressed within the equal dose range. This 




of energy-dense chow are intertwined with or are independent from changes in 
drinking behaviour. This critical issue needs to be elucidated in the future as 
previous studies have undeniably shown that the amount of ingested fluid affects 
the amount of ingested food and vice versa. It is noteworthy that the observed 
anorexigenic effect of TRP is not a result of sickness or malaise. This gives us 
greater confidence in concluding that intragastric and IP TRP engages actual 
appetite-regulatory processes rather than producing GI discomfort which then lead 
to termination of food intake. 
The pattern of c-Fos immunoreactivity evoked by 1200 mg/kg intragastric TRP and 
30 mg/kg IP TRP was fairly consistent, suggesting the key role of the brainstem 
circuitry in mediating TRP’s effects on feeding. Indeed, intragastric TRP infusion 
caused elevated NTS and DMNV neuronal activation which underscores the 
importance of the vagal afferents, whereas a slight (albeit, non-significant) increase 
in AP c-Fos levels implies a possible involvement of this sensory circumventricular 
organ [18]. An enhancement of neuronal activation within the NTS was identified 
following IP TRP. c-Fos changes were observed also in feeding-related forebrain 
areas, which suggests that TRP engages a broader network of central sites (most 
notably, the hypothalamus) either in a direct or indirect manner. After intragastric 
gavage, the most robust increase in neuronal activation occurred in the 
hypothalamic DMH, PVN and SON, the latter two also exhibited enhanced activity 
after IP TRP. Those hypothalamic regions receive input from the brainstem [49] 
and typically show enhanced activation at meal termination as well as upon 
physiological changes that signify the need to cease consumption (stomach 




the brainstem-hypothalamic circuit is consistent with the proposed role for TRP in 
the regulation of feeding for energy [25, 26]. IP TRP, which bypasses the gastric 
phase, induced a somewhat lower neuronal activation with fewer brain regions 
affected than intragastric TRP. Possibly, this reflects the effect of TRP on gastric 
mucosa and its link with the release of GI hormones (e.g. GLP-1 or CCK) [53-58]. 
Importantly, this Fos pattern is also aligned well with the effect TRP on thirst-driven 
water intake, as a subset of the activated sites mediates not just feeding, but also 
drinking behaviour [59]. For example, the SON (with VP) neurons [60] and the 
CeA, are involved in the regulation of water balance via brainstem-descending 
pathways [61-63].  
What is also important from the point of a functional relationship between TRP and 
food intake control mechanisms is the fact that both IP and intragastric TRP activate 
PVN and SON neurons that synthesise OT, a key satiety mediator. Intragastric TRP 
at an anorexigenic dose of 1200 mg/kg increases OT mRNA expression in the 
hypothalamus. OT is a 9-amino acid neurohormone [64, 65] that inhibits feeding in 
order to protect internal milieu (e.g. energy balance, stomach distension and plasma 
osmolality) [66-70]. Increased activation of OT neurons and release of OT, 
correspond with the cessation of ingestive behaviour [71-76] and centrally acting 
OT is known to stimulate the suppression of food intake [74, 77, 78]. The fact that 
OT receptor blockade with an OT receptor antagonist, L-368,899 at a dose that does 
not affect consumption, prevented TRP-driven decrease in chow intake strongly 
suggests that the involvement of the OT circuit is required for satiating effect of 
TRP to occur. Importantly, this was evident in the case of both intragastric TRP and 




gastric mucosa or its administration route bypasses the gut, its anorexigenic action 
relies on activation of OT neurons. L-368,899 being ineffective in alleviating IP 
TRP’s effect on deprivation-induced water intake suggests that while OT might still 
participate in this process, it is not essential for drinking behaviour reduction after 
IP TRP. Considering that IP TRP-induced c-Fos immunoreactivity in the PVN and 
SON spreads beyond the identified OT neurons, it is quite possible that PVN and 
SON cells synthesising other neuropeptides, such as VP, are involved in the thirst 
effects [60]. As the release of the OT and OT neuronal activity coincide with 
satiation-associated termination of feeding [73-76], and a similar effect on OT 
system is stimulated by administration of peptides that promote satiation (e.g. 
alpha-MSH, CCK, GLP-1) [51, 79-82]. One should note that the OT neuronal 
activation (similarly to the general c-Fos profile throughout the brain) in animals 
infused with intragastric TRP was higher than in IP TRP-treated individuals. It may 
reflect the direct effect of TRP on gastric mucosa and, consequently, a hypothetical 
link it with, e.g., a release of select gut hormones, as intraduodenal TRP increases 
of CCK, glucagon, and GLP-1, levels [83]. Nonetheless, the present data show that 
the effect of both intragastric and IP TRP on OT neuronal activation parallels that 
induced by food loads as well as by neuroactive agents that cause termination of 
consumption. That finding combined with the fact that TRP induces simultaneous 
activation of the key appetite-related brainstem circuit instils confidence in that 
TRP-derived hypophagia is indeed of physiological relevance and that the pathways 
involved in that process encompass OT. Further studies involving modification of 




disruption of brainstem-hypothalamic pathways, would shed more light on the role 
of central circuitry in TRP-induced hypophagia. 
It should be noted that OT receptor is also expressed in the peripheral tissues, for 
example, in the adipose tissue, uterine smooth muscle and bone cells [84-87]. 
Studies to date have shown that short-term appetite changes are driven mainly by 
the central OT receptor, therefore, in short-term feeding studies the use of 
peripherally administered BBB-penetrant OT receptor ligands is commonly used 
without the risk of having the effects altered via peripheral mechanisms. The OT 
receptor antagonist used in the current experiments had been thoroughly studied in 
the context of its transient effects on appetite, and the outcomes indicate that 
regardless of whether it is injected centrally or IP, it produces the same consumption 
profile [48, 88-90].  It should be emphasised, however, that should a long-term 
treatment be attempted, then central administration of L-368,899 would be 
preferred, thereby removing the confound of the peripheral pool of the OT receptor. 
In retrospect, the analysis of c-Fos immunoreactivity in animals that were treated 
with the OT receptor antagonist would be useful. One of the expected differences 
would be a decreased activity within the brainstem areas associated with meal 
termination that are rich in OT receptor. Combining this experimental approach 
with analysing the OT plasma levels could serve as a foundation of a future research 
project that draws upon the findings presented herein. This would enable us to 
elucidate the contribution between central and peripheral effects of OT relating to 




Importantly, as stress is known to activate both PVN and SON OT neurons [91, 92], 
one should note that the control groups in our experiments provide an adequate 
baseline to compare similar administration routes with TRP and vehicle. Attempts 
were made to try and limit the level of stress experienced by animals, especially 
following the oral gavage procedure. Animals were always returned to their home 
cages following infusion and then allowed 20 minutes before tastant given. Rats 
were avoided for intragastric infusion as individuals demonstrated high levels of 
stress following the procedure – much lesser response observed in mice.   
One of the most striking outcomes of these studies is the fact that TRP is such a 
poor inhibitor of feeding for reward, especially of calorie-dilute solutions. It is 
particularly surprising given the functional link between TRP and OT.  Especially 
that the OT receptor is highly expressed in brain regions associated with food 
reward (e.g. VTA, Acb and BNST), with PVN OT neurons innervating these key 
regions [93-96]. Also, OT receptor antagonist, L-368,899, prolongs intake of 
palatable sweet solutions, whereas intra-VTA and intra-Acb OT infusions suppress 
palatability-driven sucrose consumption, reversible with a pre-treatment of L-
368,899 [47, 48]. Hence, the fact that TRP does not potently affect the portion of 
feeding driven by pleasure suggests that only a subset of hypophagia promoting OT 
neurons is engaged by this amino acid. 
Overall, the findings outlined in this thesis strongly indicate the appetite 
suppressant role of TRP in energy intake. Also, it is suggested that OT – as part of 




important neural mediator of TRP-driven reduction in food consumption regardless 
of whether TRP is delivered intragastrically or IP (thus, bypassing the gut).  
Importantly intragastric and IP TRP did not cause the development of a CTA, 
indicating that the observed hypophagia does not stem from aversion. One should 
note that the mouse model might have benefited from an inclusion of an additional 
experiment verifying our CTA induction paradigm, in which animals would be 
injected IP with saline and LiCl. However, previous studies published by our group 
have verified effectiveness of this particular experimental setup in mice (e.g., [97]) 
and therefore the institutional ethics regulations prevented us from repeating the 
experiment yet another time.  
Furthermore, the alanine control for osmolality in intragastrically treated mice 
provided evidence that changes in osmolality that parallel those associated with 
TRP administration do not by themselves induce hypophagia. Therefore, the 
anorexigenic effect of TRP was specific to this amino acid, but not to others that 
produce a similar osmolality profile. Since the anorexigenic dose of IP TRP was 
more than 10 times lower than after intragastric administration, the likelihood of 
any significant changes in the osmotic plasma profile after the treatment was so low 
that it did not warrant including additional amino acid IP controls. One could debate 
as to whether intragastric alanine or water would serve as a better control for TRP, 
however, using alanine would add more confounding factors to the analysis 
(including possibly some unforeseen behavioural changes seemingly unrelated to 
appetite, but eventually affecting food intake as a secondary outcome). In c-Fos 




c-Fos expression profile in regions associated with osmotic regulation (such as the 
SON which encompasses VP neurons [59, 60]), in animals that were treated with 
alanine compared to TRP. 
There are some limitations of the studies, and these were minimised where possible. 
Firstly, one noticeable limitation was the use of two rodent species (mouse – oral 
gavage and rat – IP injection) alongside differing methods of TRP administration. 
The model species were selected based on the fact that in our pilot studies, unlike 
mice, rats did not respond well to the stress of gavaging, as indicated by large 
discrepancies in food intake within treatment groups and generally lower-than-
expected feeding values. Therefore, in order to minimise the risk of stress 
influencing the outcomes of actual experiments, the intragastric route of 
administration was matched with a species that was less susceptible to displaying 
treatment-induced anxiety/discomfort. Furthermore, differences in responsiveness 
to hypo/hyperphagic treatments between mice and rats are rare. Many orexigens 
(e.g. ghrelin) and anorexigens (e.g. OT, CCK) are known to be effective in both 
species. For example, ICV administration of ghrelin in rodents produced a dose-
dependent increase in both food intake and bodyweight [98]. Of interest, peripheral 
OT infusions in diet-induced obese mice/rat models reduces food intake whilst 






One of the most urgent emerging issues in order to better understand TRP-driven 
hypophagia is a systematic identification of hormonal, neural and cellular processes 
that bridge TRP and activation of feeding-related neural networks, including those 
that encompass OT. Based on the results presented herein and in other reports, it is 
most plausible that TRP acting peripherally utilises several concurrent processes to 
induce a reduction in food intake. Initial evidence suggests the importance of the 
aforementioned GI hormonal route. However, there is also a critical link between 
TRP and 5-HT and melatonin: both of these affect (directly and indirectly) sleep, 
mood, anxiety and other processes that translate to altered appetite [17, 101-105]. 
There is also a possibility of TRP acting at cells directly [57, 106].  
Furthermore, the experimental work presented here determined meal-associated 
changes in appetite following acute administration of TRP. However, in order to 
mimic therapeutic application of this approach in the basic research setting, one 
would have to consider the effects of chronic TRP administration. Would a lower 
subthreshold anorexigenic dose received chronically overtime have an 
accumulative effect on bodyweight and food intake? Studies to date – also those 
pertaining to other amino acids – have predominantly focused on the effect of 
episodic intake after amino acids dosing [18, 24, 26]. Perhaps, amino acids that 
possess hypophagic tendencies at subthreshold doses could exhibit an enhanced 
combined effect whilst avoiding the need for high dosages. In regards to TRP, it is 
well documented that the transporter LAT1 is responsible for the competitive 
transport of LNAA across the BBB [107-109]. Therefore, by influencing the ratio 
of other LNAA’s to TRP may be able to enhance the uptake of TRP even at a lower 




been shown to be influenced by alterations in dietary availability [112]. One of the 
next logical long-term steps would be to manipulate TRP levels in the diet.  
These questions are of paramount importance, especially in the context of utilising 
TRP in functional food-based anti-obesity strategies and as a potential ‘nutri-
pharmaceutical’. Only by answering them will we be able to determine whether and 
how to supplement TRP in order to maximise its beneficial effects on energy intake, 
while reducing the risks that stem from the vast complexity of diverse physiological 






The overarching aim of this doctoral thesis was to examine whether TRP suppresses 
food intake via energy balance- and/or reward-related mechanisms. The findings of 
the study are: 
 Intragastric and IP TRP pretreatment reduces feeding for energy. 
 TRP is a weak inhibitor of palatability-driven consumption: only higher IP 
TRP doses reduce intake of nil- or low-calorie palatable solutions, whereas 
intragastric TRP is ineffective. 
 Anorexigenic effects of TRP do not stem from sickness/malaise. 
 Both intragastric and IP TRP reduces thirst-induced water intake. 
 TRP increases activation of several key feeding-related brain areas, 
especially in the brainstem and hypothalamus. 
 TRP-driven reduction in food but not water intake might, at least to some 
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